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Abstract
In our daily life, we come across situations where we meet unanticipated
challenges, we must take certain decisions, pay attention, be flexible and inhibit
impulsive actions to achieve goal directed behaviour. During these processes, we
unknowingly use sets of interdependent cognitive processes collectively called ‘executive
function’. Executive function is mainly regulated by the frontal lobe. Impaired executive
function is associated with disorders such as schizophrenia, Alzheimer’s disease, autism
and attention deficit hyperactivity disorder (ADHD).
In this thesis, we investigated neurotransmitters and interactions among them
regulating executive function. Further, we investigated mechanisms underlying those
interactions mediating executive function in rats using an operant conditioning-based setshifting task, a common and validated test in animals to assess executive function. In our
first study, we identified for the first time that systemic injections of dopamine D1 and
glutamate N-methyl-D-aspartate (NMDA) receptor antagonists cause impaired setshifting and increased the occurrence of perseverative errors only after combined
administration at doses that failed to affect set-shifting following separate injections. The
discovery of this novel synergistic effect of glutamate and dopamine antagonists on setshifting prompted us to undertake our second study to determine if such synergy occurs
within the medial PFC (mPFC)- an important brain area associated with executive
function in rodents. Our results confirmed that mPFC is a site where seemingly mild
suppression of glutamate and dopamine activities, similar to that has been reported in
schizophrenia brains, may act cooperatively to manifest deficits in executive function via
increasing perseverative errors. Our third study was to identify molecular mechanisms
underlying such synergy. We found that protein kinase A (PKA) and extracellular signalregulated kinase (ERK1/2) signaling cascades transduce this effect, with ERK1/2
phosphorylation in mPFC neurons as an obligatory step for set-shifting.
The present results have substantially advanced our understanding of the
mechanisms underlying executive function. Our results also point to potential novel
intracellular targets for therapeutic intervention in cognitive deficits.
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Chapter 1

2

Introduction
1.1 Executive functions
While driving a car, upon reaching a traffic signal that has just turned amber, the
first thought that comes to our mind is about the distance of the car from the signal and
how much time remains before the light turns red. Depending on the assessment, if there
is sufficient time, we keep driving and get through the traffic signal safely. Alternatively,
if we think that the signal will turn red before we pass through it, we apply the brakes to
stop the car at the signal. In the above example, our brain works with enormous speed to
calculate our distance from the traffic signal, probable time left before light turns red, are
there any pedestrians looking for crossing the road, other vehicles around our car, etc.
Information from our current sensory environment and relevant past experiences are
considered and processed at very fast rate making it possible to drive a car safely. This is
an example of ‘executive function’ where multiple interdependent cognitive processes
work together synchronously to carry out a goal directed behaviour.
Executive function is a higher order cognitive ability comprising working memory,
behavioural flexibility (set-shifting and reversal learning), attention, problem solving
ability and inhibition (Gilbert and Burgess 2008; Diamond 2013; Miyake et al. 2000).
These processes facilitate us to think, plan, get engaged, learn from the outcomes and
tackle unfamiliar circumstances to carry out goal-directed behaviours in our day-to-day
life (Elliott, 2003). As described by Funahashi (2001), executive function is ‘a product of
the co-ordinated operation of various processes to accomplish a particular goal in a
flexible manner’. It would be difficult to perform daily activities without proper
executive functioning ability (Damasio, 1994). Various central nervous system (CNS)
disorders including schizophrenia, Alzheimer’s disease, autism and attention deficit
hyperactivity disorder (ADHD) show deficits in executive function (Millan et al., 2012).
Executive function impairments may affect cognition, behaviour and personality.
Behavioural component involve difficulty in pursuing goals, problem-solving ability and
switching between possible strategies i.e. behavioural flexibility. These impairments
affect a patient’s social life drastically and lead to immense economical loss to the
individual, their family and society.
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Executive functioning: Components
Conventionally, executive function was considered as a single construct, associated
with higher order cognitive skills (Shallice, 1988). Executive function has also been
conceptualized as a balanced association of multiple cognitive processes bringing about
higher order cognitive function (Stuss and Alexander, 2000). As per the latter concept,
there are three core components of executive functions: inhibition, working memory, and
behavioural flexibility; all of which are interrelated, interdependent and work together
(Miyake et al., 2000; Lehto et al., 2003).

Inhibition
In the example of executive functioning given in the first paragraph, when we see
a traffic light turns amber from green, our brain calculates the probable time left to pass
through the signal before it turns red. If that time window is too short, our brain
commands to apply the brakes and stop the car at the signal. This self-inhibition is one of
the components of executive functioning (Mäntylä et al., 2010). Inhibitory control
involves regulating one’s thoughts, attention and emotions. It helps us to focus on our
aim in the presence of distractions. Inhibitory control allows us to avoid impulsive
responses and to think before making a choice. Inhibition works with other functions like
attention or working memory, and from our previous learnings help us to avoid making
incorrect choices. Impaired inhibition can profoundly affect our daily activities causing
us to react impulsively. CNS disorders including schizophrenia and ADHD, or conditions
like addiction and mania display pathology of impaired inhibition (Gut-Fayand et al.,
2001; Li and Sinha, 2008; Dumais et al., 2011).
The frontal lobes are thought to be associated with the regulation of inhibition. It
was found that patients with frontal damage seized anything in front of them on the
clinician’s desk, as those objects provided affordances, and inhibition was needed to stop
motor system to avoid such reactions (Lhermitte, 1983). In a lab experiment, Wallis et al,
(2001) showed that monkeys with lateral PFC damage cannot control behaviour of
reaching for food kept behind a transparent barrier provided, that they were trained to
reach around to get the food previously.
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Representative tasks used to assess inhibitory control
Inhibitory control can be assessed using a number of behavioural tests such as the
Stroop test (Macleod, 2005), Flanker Task, and Go/No-Go tasks. In the Stroop test, a
subject sees a series of colour names (black, blue, yellow, green, red). These words
appear in different colours, sometimes as congruent (e.g., the word blue, written in blue),
and sometimes non-congruent (e.g., the word blue, written in red). The subject is
instructed to indicate, as quickly and accurately as possible, the colour in which the word
is written, regardless if that matches the word itself.
Our ability to suppress inappropriate responses in a particular context can be
assessed by computer-based Flanker Task (Eriksen and Eriksen, 1974). During each trial,
the subject is presented with a set of arrows on screen as shown below (arranged as A, B,
C, or D) and a correct response is made by choosing either a left or right button,
dependent on the direction of the central arrow. The subject’s ability to avoid incorrect
responses is assessed in this task.

A
B
C
D
Figure 1.1 Flanker Task (Eriksen and Eriksen, 1974)
In a separate type of test, Go/no-go task, subjects are required to press a button when a
stimulus appears; however, on a trial when a particular stimulus is presented, the subject
must inhibit from pressing the button (Cragg and Nation, 2008).

Working memory
Working memory is an important component of executive function, which is
characterized by the ability to hold information in the mind temporarily while processing
it (Baddeley, 2012). An example of working memory would be solving a math problem
without using paper and pen. Another example of working memory is finishing the
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meaningful sentence while we are talking, as we need to keep track what has been said
already and what we should say in order to finish the sentence. Working memory helps us
to make sense of things which unfold over time as we require to hold in our mind what
happened earlier and relating that to what comes later (Lett et al., 2014).

Representative tasks used to assess working memory
Working memory tasks are designed such that the subject must keep the
information provided in mind temporarily and process it to make a correct response.
Asking a subject to reorder the objects they have read, heard, smelled or seen is an
excellent measure of working memory. For example, repeating the numbers flashed on
screen (2, 7, 8, 1, 9) in numerical order (1, 2, 7, 8, 9) or reordering the items just heard
based on their size (cat, dog, rat, elephant).
In Corsi block-tapping task, a tester taps the objects on the screen and following
that, the subject must tap those objects in the same or opposite sequence in order to get
the trial correct (Berch et al., 1998; Cragg and Nation, 2007). In the self-ordered pointing
task (SPOT), a subject sees 12 objects on the screen (drawings or abstract designs), and is
asked to click one item at a time in any order without repeating the choice until all items
are clicked. After each choice, feedback is given. In addition to the tasks mentioned,
researchers have used the N-Back task to assess inhibition (Owen et al., 2005; Kane et
al., 2007), although it requires high levels of executive function, such as selective and
sustained attention, thus not making the task selective for working memory (Miller et al.,
2009).

Cognitive flexibility
Cognitive flexibility, which is a core feature of executive function, builds on the
integration of working memory and inhibition. When we come across a problem which
could not be solved by the way we know, we take a step back and try to solve it using
different approaches (changing our point of view). A simple example of behavioural
flexibility occurs when attempting to open a door; we elect to either pull it inside or push
it outside. If pulling does not work, we change our approach and try to push the door
outside.
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Representative tasks used to assess cognitive flexibility
To investigate behavioural flexibility, researchers use set-shifting and taskswitching paradigms (Monsell, 2003). The Wisconsin card sorting task (WCST) is one of
the oldest tasks to assess behavioural flexibility in patients suffering from CNS disorders
like schizophrenia (Braff et al., 1991; Gooding et al., 1999; Prentice et al., 2008). In
WCST, reference cards with stimuli of different coloured shapes are flashed on a screen.
For each trial, a new test card is offered below the reference cards. The subject must then
match the test card to one of the reference cards based on the colour, shape, or number of
the stimuli presented on it. Feedback is provided after each match, enabling the subject to
acquire the correct rule of sorting the cards. Following a certain number of correct
responses, the rule is changed without notice, and the subject must shift to a new mode of
classification to get the trials correct. In set-shifting, ability of subject to switch to new
strategy is assessed in presence of old strategy which is not valid anymore.
As its name implies, task switching involves two tasks and the subject’s ability to
switch from one task to the other. For example, subject is shown a coloured square with a
number in the middle. Both sides of screen have a set of response keys: a key asking if
the number flashed is odd or even, and the other is if the number is lower or higher than
10. Now based on the colour if it is black, the subject needs to answer higher or lower
and if the colour is white, answer should be even or odd.
In both set-shifting or task-switching, errors are due to difficulty in inhibiting
previously correct strategy, and this tendency is termed as ‘attentional inertia’ (Dick,
2012; Longman et al., 2014). It was found that the behavioural flexibility is developed in
children by age of 7-9 (Gupta et al., 2009); during adulthood, it functions at the best and
declines during old age (Kray and Lindenberger, 2000).

Neuroanatomical correlates of executive functioning in human
Historically executive functioning has been thought to be associated with frontal
lobes. Patients with frontal cortex damage have shown impaired planning, organizing and
behavioural disinhibition (Smith and Jonides, 1999; Stuss and Alexander, 2000; Roca et
al., 2010; Sira and Mateer, 2014). In laboratory settings, such patients have also shown
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impairments in WCST (Milner, 1963; Nelson, 1976; Stuss et al., 2000). In addition to
this, patient population suffering from schizophrenia, a disorder with a prefrontal
pathology, also show executive function impairments (Gooding et al., 1999; Everett et
al., 2001; Prentice et al., 2008). Further, brain imaging studies in healthy individuals have
shown that the dorsolateral prefrontal cortex (dlPFC) is one of the areas that is activated
while performing executive function tests (Funahashi, 2001; Monchi et al., 2001). These
observations over the years, led to the conclusion that executive function is strongly
associated with the PFC, and hence, ‘executive function’ and ‘frontal lobe function’
became almost interchangeable terms (Ardila, 2008).
Although the association between the PFC and executive functioning has been
well-documented, brain imaging studies have also identified the contribution of other
brain areas in executive functioning (Monchi et al., 2001; Collette and Van Der Linden,
2002; Salmon and Collette, 2005; Alvarez and Emory, 2006; Collette et al., 2006).
Neuronal system associated with executive function is complex and interrelated (Gilbert
and Burgess, 2008). The PFC is highly connected with almost all brain regions including
parietal, temporal, occipital lobes as well as subcortical and limbic regions, and they
function interdependently (Adcock, 2000; Manoach et al., 2000; Stuss and Alexander,
2000; Cole et al., 2012; Zhang et al., 2014). Because of this, areas involved in executive
functioning may be greatly expanded. Taken together, impaired executive functioning
may be an outcome of PFC pathology, or it may be related to network disconnections or
damage to brain regions including mediodorsal thalamus (MDT), striatum, accumbens
etc.

Executive functioning in rodents
For decades, scientists have routinely used rodents as a main model for brain
research. Numerous studies have used rats to study executive functions including
working memory, attention, behavioural flexibility (set-shifting and reversal learning)
and decision making (Birrell and Brown, 2000; Miller, 2000; Mirza and Bright, 2001;
Floresco et al., 2009; Auger and Floresco, 2014). Studies have revealed the role of
different brain nuclei including PFC, striatum, nucleus accumbens (NAc) and ventral
hippocampus in executive functions (Felix and Levin, 1997; Crofts et al., 2001; Brown
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and Bowman, 2002; Dalley et al., 2004; Floresco et al., 2006a, 2006b, 2009;
Boulougouris et al., 2007; Brooks et al., 2012; Lindgren et al., 2013). In our experiments,
we focused on set-shifting as a measure of behavioural flexibility and studied
neurotransmitters and the mechanisms associated with set-shifting.

Behavioural flexibility in rodents
The ability to reverse a choice behaviour or the ability to shift a response rule
when a previously learned strategy does not work has been widely used as a measure of
behavioural flexibility. Analogous to clinical WCST used by Grant and Berg (1948), setshifting tasks have been commonly employed for assessment of cognitive flexibility in
rodents. These tasks involve training animals to follow a certain rule and once they
acquire that learning (i.e. form an ‘attentional set’), the rule is changed and ability of
animals to figure out the new rule in presence of old one is assessed. Rats are required to:
a) inhibit previously correct strategy which is no longer valid b) keep looking for a new
strategy which works and c) once figured out, keep using new strategy without going
back to original one (Floresco et al., 2008). The stimuli used in set-shifting are called
‘dimensions’ and traditionally they have been visual, related to texture, spatial or
olfactory in nature. Depending on the stimuli used, there are two versions of set-shifting:
a) Intra-dimensional and b) Extra-dimensional set-shifting. After forming an initial set, if
the same type of stimulus used during set-shifting (i.e. after rules are changed), then it is
called as intra-dimensional set-shifting, and if the different type of stimulus is used for
latter phase of set-shifting, then it is called as extra-dimensional set-shifting. In
accordance with clinical studies in patients with prefrontal pathology, rats with PFC
lesions face more difficulties while performing extra-dimensional set-shifting than intradimensional set-shifting (Dias et al., 1997; Birrell and Brown, 2000). Different types of
paradigms have been used to assess set-shifting in rodents. The most common examples
are: a) digging task b) maze task c) operant conditioning-based task.

Digging task
Digging tasks have been used widely and successfully by researches to assess setshifting in rodents (Barense et al., 2002; Young et al., 2010; Kos et al., 2011; Heisler et
al., 2015). Birrell and Brown (2000) used the natural tendency of searching for food in

9

rats. As shown in Figure 1.2, diverse stimulus dimensions are used to distinguish between
bowls: digging media filling the bowls, olfactory cues added to the medium and the
texture of the bowls. Rats use tactile or olfactory cues to retrieve food rewards in this
task. For example, food restricted rats are trained to dig in a bowl with filling medium
smelling like mint to obtain food rewards during every trial associating mint odour of the
medium with reward. This is called initial set formation. Next, during the set-shifting,
rats must switch from olfactory cue to the type of texture of the bowl (sand paper) as a
strategy to get rewards. So, in latter phase of the task (set-shifting), rats must dig in the
bowl with sand paper texture regardless of olfactory stimulus.
Advantages of this task are that it requires simple set up of instruments, and the
same rat could be tested more than once using different stimulus dimensions (Wallace et
al., 2014). Although it also has certain disadvantage like more interference of researcher
during the task. Furthermore, training rats takes more time as compared to the operant
task (described below).
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Figure 1.2 Schematic of the digging task used to assess behavioural flexibility in
rodents.
In the digging task, rats are trained to dig in bowls by discriminating them based on odour,
texture or the medium filled in bowls. In the given example, relevant dimension is odour
and rats must dig in bowl smelling like mint to get food rewards (initial set formation).

During extradimensional set-shifting, rats must dig in the bowl with sand paper like texture
regardless of odour of the bowl.
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Maze task
In the maze task, a plus maze is used where rats shift between two stimulus
dimensions i.e. visual-cue and spatial-based discrimination strategies (Ragozzino et al.,
2003; Stefani et al., 2003; Floresco et al., 2009). Food restricted rats are initially trained
(initial set formation) to retrieve food rewards by entering in an arm with distinctive
visual cue (brightened or darkened arm; Figure 1.3). For the set-shifting, rat must learn to
turn in specific direction (either left or right) regardless of visual-cue in order to retrieve
the food rewards. Simple experimental set up is an advantage of using maze task.
Drawback of maze task would be lack of automaticity as well as an experimenter has to
handle rats after every trial.

Figure 1.3 Schematic of the maze task used to assess behavioural flexibility in rodents.
For maze-based extradimensional set-shifting task, rats are trained to use a visual-cue
discrimination strategy i.e., entering the arm with the visual cue by turning to right or left
(initial set formation). During set-shifting, to earn food rewards, rats must use a response
discrimination strategy, and make a 90° right turn to enter in an arm to get food reward
regardless of position of visual-cue stimulus.
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Operant-based task
Floresco et al. (2008) has adapted the same approach for set-shifting as that of the
aforementioned plus maze. In an operant box, food restricted rats are trained to press the
lever associated with an illuminated visual-cue stimulus light to earn food rewards as a
part of initial training (visual-cue discrimination; Figure 1.4). Once rats achieve the
criterion for visual-cue discrimination, on the next day, contingencies are altered and now
rats must respond on one particular lever (response discrimination) during every trial to
get food rewards regardless of location of illuminated visual-cue stimulus light.
Advantage of using this task is that operant conditioning is fully automated, thus
reducing the interference of an experimenter. Furthermore, parameters like the type of
errors, omissions and latency to response are precisely recorded in trial by trial manner.
In addition to this, the associated training procedure in this task is short and robust as
compared to maze or digging tasks. Moreover, operant conditioning does not have strong
spatial or olfactory demands (Bizon et al., 2012).

Figure 1.4 Schematic of operant-based task used to assess behavioural flexibility in rodents.
In operant-based extradimensional set-shifting, rats are trained to respond on the lever with
illuminated visual-cue stimulus light (i.e. rats use visual-cue discrimination strategy to discriminate
between the levers). On set-shifting, rats must follow a response discrimination and press one
particular lever (right or left) regardless of the position of the illuminated visual-cue stimulus light.
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Error classification
Errors committed during set-shifting can be classified in to three categories:
Perseverative errors: Inability of rats to switch to new strategy give rise to this type of
errors during set-shifting. Perseverative error is an index of how quickly animals can
learn use of the correct strategy.
Regressive errors: While performing set-shifting even though rats try a novel strategy that
results in a correct trial (food reward), they often go back to the original rule which is
irrelevant during set-shifting making regressive errors. These regressive errors are an
index of the rat’s ability to maintain the newly acquired strategy.
Never-reinforced errors: While performing set-shifting, animals try to explore new
response choices to figure out the novel strategies which could result in a correct
response. During this process, rats try certain approaches that they never learnt during the
initial acquisition, only to discover that it also does not yield a food reward during the
set-shifting task. This type of error is called a never-reinforced error. Never-reinforced
errors are an index of how readily rats can ignore certain strategies which do not result in
a correct response.

Neural circuits subserving behavioural flexibility in rodents
Behavioural flexibility is not a unitary phenomenon, rather, it has been
conceptualized as different functions working together. To finish set-shifting
successfully, animals must meet three requirements of the task: a) Inhibit a previously
correct strategy which is now irrelevant during set-shifting. b) Keep looking for a new
strategy which could give food rewards. c) Once a new strategy is found, keep using it,
and avoid going back to the previously correct rule. Because different brain nuclei are
associated with different components mentioned, a successful set-shifting performance is
thought to be the result of brain circuitry involving number of brain regions rather than
one specific nucleus (Block et al., 2007; Floresco et al., 2009).
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Prefrontal Cortex (PFC)
From the studies in human, non-human primates as well as rodents, it is well
known that PFC is strongly implicated in behavioural flexibility (Brown and Tait, 2016).
Inactivation or damaging medial prefrontal cortex (mPFC) in rat results in impaired setshifting performance without affecting initial learning (initial set formation) (Ragozzino
et al., 1999a; b; Floresco et al., 2008). Following inactivation/lesioning of mPFC,
perseverative errors were found to be increased (rats are not able to switch to new rule,
hence repeating the same incorrect response despite not receiving any food rewards). On
the other hand, inactivation of orbitofrontal cortex (OFC) caused impaired reversal
learning in rats (Ghods-Sharifi et al., 2008). Interestingly, inactivation of mPFC did not
affect reversal learning, and lesioning OFC did not have any effect on set-shifting;
findings which suggest that although set-shifting and reversal learning are components of
behavioural flexibility, they are regulated by different regions of the PFC. Furthermore,
increased perseverance is the abnormality shared by rats with mPFC damage and the
patients with schizophrenia with frontal lobe pathology in set-shifting and WCST
respectively, suggesting PFC has similar role in executive functioning across species (For
review, Brown and Tait, 2016).

Mediodorsal Thalamus (MDT)
Mediodorsal thalamus has reciprocal connectivity with the PFC (Groenewegen,
1988). This anatomical association with PFC suggest that MDT may contribute to
behavioural flexibility. The role of MDT in a simpler form of behavioural flexibility i.e.,
reversal learning is controversial as some studies report impairments in reversal learning
following MDT lesioning (Means et al., 1975; Chudasama et al., 2001; Parnaudeau et al.,
2015) while others did not see any impairments (Tigner, 1974; Beracochea et al., 1989).
On the other hand, lesioning MDT produced increased perseverance in rodents in a setshifting task which is a more complex behaviour than reversal learning (Hunt and
Aggleton, 1998). Furthermore, inactivating MDT did not affect the initial learning phase
in set-shifting, suggesting the MDT is associated with shifting strategy and not general
learning (Block et al., 2007).
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Clinical brain imaging studies have shown activation of MDT following incorrect
response in WCST suggesting it may be acting as a trigger to switch the strategy (Monchi
et al., 2001). Thus, across species, MDT is associated with behavioural flexibility, and
abnormal functioning of MDT results in increased perseverance.

Nucleus Accumbens (NAc)
Floresco et al. (2006a), investigated effect of inactivation of NAc-Core and NAcShell on maze-based set-shifting task performance. It was found that inactivation of NAcCore did not affect initial acquisition but impaired set-shifting. Type of errors committed
during set-shifting were ‘regressive’ and ‘never-reinforced’; error profiles different than
perseverative error profile associated with mPFC or MDT lesioning. Increased regressive
errors meant that rats were not able to hold on to the new strategy and more often they
went back to the previously correct strategy suggesting that NAc-Core plays important
role in maintenance of a novel response. Never-reinforced errors are considered as an
index of how quickly rats can get rid of the strategy which would not give food pellet
(correct response) (Floresco et al., 2008). An increase in never-reinforced errors suggests
that NAc-Core mediates the inhibition of unsuitable response choices through learning of
a novel strategy. Inactivation of NAc-Shell neither affected initial acquisition nor the setshifting.

Striatum
Inactivation of striatum did not affect initial acquisition in rats but impaired setshifting. Errors committed were regressive in nature suggesting that striatum plays an
important role in maintaining newly learnt strategy (Ragozzino et al., 2002b; Haluk and
Floresco, 2009).

Neurotransmitters associated with behavioural flexibility
Various pharmacological studies in animals have provided evidence for
involvement of different neurotransmitter systems regulating set-shifting. Most
commonly, gamma-Aminobutyric acid (GABA), dopamine, glutamate and have been
studied for their role in in behavioural flexibility.
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GABA
Involvement of GABAergic neurotransmitter in cognition has been the topic of
discussion for last two decades. GABA has got the attention of researchers due to its
involvement in the prefrontal pathophysiology of schizophrenia and possible role in
cognitive impairments associated with schizophrenia (Coyle, 2004; Lewis et al., 2008;
Vinkers et al., 2010; Lett et al., 2014). Since then several studies in human as well as in
animals have investigated the role of GABA in executive functions including working
memory, attention and behavioural flexibility (Michels et al., 2012; Auger and Floresco,
2014; Banuelos et al., 2014; Chen et al., 2014).
Enomoto et al. (2011) studied effect of intra-mPFC infusion of bicuculline
(GABA-A receptor antagonist) on set-shifting. It was found that, bicuculline significantly
impaired set-shifting in rats. Impaired set-shifting resulted from increased perseverative
errors without any effect on regressive and never-reinforced errors; an error profile
similar to mPFC inactivation studies (Ragozzino et al., 1999a; Floresco et al., 2008).

Dopamine
Historically, the role of prefrontal dopamine has been examined for its
contribution in executive functioning. Evidence from human as well as animal studies
have confirmed that normal dopamine receptor functioning (D1/D2) is essential for
normal executive functions including working memory, attention and behavioural
flexibility (Sawaguchi and Goldman-Rakic, 1994; Müller et al., 1998; Misener et al.,
2004; Vijayraghavan et al., 2007; Floresco, 2013). Furthermore, decreased number of
dopamine D1 receptors in dlPFC of schizophrenic patients was correlated with the poor
performance on a working memory task (Okubo et al., 1997; Akil et al., 1999).
Considering the role of dopaminergic neurotransmitter in cognitive processes,
researchers studied the involvement of dopamine in behavioural flexibility using
pharmacological approaches in rodents. For example, intra-mPFC infusion of dopamine
D1 receptor antagonist impaired set-shifting without affecting initial acquisition
(Ragozzino, 2002a; Gauthier et al., 2014). Interestingly, stimulation of D1 receptors did
not improve set-shifting (Floresco et al., 2006b), a finding in line with Fletcher et al.
(2005), where acute intra-mPFC infusion of D1 receptor agonist treatment per se did not
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affect set-shifting but reversed set-shifting impairments in amphetamine sensitized rats.
Further, intra-mPFC infusions of dopamine D2 receptor antagonist impaired set-shifting
set-shifting by increasing perseverance whereas stimulation of D2 receptors in the mPFC
did not affect set-shifting. In addition to this, while D4 receptor agonist impaired setshifting performance, stimulation of D4 receptors by an agonist improved the set-shifting
above control level (Floresco et al., 2006b). These findings indicate that the “inverted-U”
shaped function underlying dopamine receptor regulating working memory does not
appear to hold true for set-shifting function mediated by the PFC. This finding is in
accordance with

Glutamate
In the brain, glutamate is a major excitatory neurotransmitter. Glutamate Nmethyl-D-aspartate (NMDA) receptors regulate synaptic plasticity i.e. long-term
potentiation (LTP) and cognition (Villarreal et al., 2002). NMDA receptor antagonists
including ketamine and phencyclidine (PCP) cause cognitive symptoms of schizophrenia
in healthy volunteers or exacerbate these impairments in schizophrenic patients (Malhotra
et al., 1996, 1997; Coyle and Tsai, 2004; Morgan et al., 2004; Morris et al., 2005). This
led to glutamatergic hypothesis of schizophrenia where NMDA altered functioning was
related to impaired cognition in schizophrenic patients (Coyle, 1996, 2006; Tsai and
Coyle, 2002; Paz et al., 2008).
Due to deep association of glutamate with cognition, researchers investigated if
glutamate is involved in controlling executive functions in humans as well as animals. In
a clinical study (Krystal et al., 2000) found that administration of sub-anesthetic dose of
ketamine in healthy volunteers impaired their performance in WCST. In animal studies,
normal functioning of NMDA receptors was found to be essential for working memory as
well as attention (Murphy et al., 2005; Baviera et al., 2008; Smith et al., 2011; Wang et
al., 2012b; Su et al., 2014; Auger and Floresco, 2017).
In animals, behavioural flexibility was found to be regulated by NMDA receptors.
Intra-mPFC infusion of NMDA receptor antagonist (MK-801) impaired set-shifting and
increasing perseverative errors in animals (Stefani and Moghaddam, 2005). This finding
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was replicated by acute or repeated systemic injections of either MK-801, PCP or
ketamine in animals (Rodefer et al., 2005; Egerton et al., 2008; McLean et al., 2008).

Dopamine-glutamate interactions
Both dopamine and glutamate abnormalities in the PFC are thought to be
associated with cognitive pathology of schizophrenia (Akil et al., 1999; Coyle, 2006).
Role of individual neurotransmitters regulating executive functions has been studied.
Although the interaction between dopamine and glutamate regulating different
behaviours has been investigated, its role in executive function is yet to be explored
sufficiently.
A number of studies have investigated interaction between D1 and NMDA
receptors regulating different behaviours. It was found that combined infusion of subeffective doses of D1 and NMDA receptor antagonists in the mPFC or NAc-Core
impaired instrumental learning in rats (Smith-Roe and Kelley, 2000; Baldwin et al.,
2002b). Similarly, co-infusion of NMDA and D1 receptor antagonists on contralateral
sides of amygdala impaired glucose-conditioned learning of flavor preference in rats; coinfusion of one of the antagonists on one side and vehicle on the other side did not show
any effect on behaviour suggesting that, blockade of both D1 and NMDA receptors was
essential to cause impairment (Touzani et al., 2013). Furthermore, functional striatal
NMDA channels are needed to control D1-stimulated locomotor behaviour (Kreipke and
Walker, 2004). In addition to this, deletion of NR1 subunit of NMDA receptors in the
NAc was found to attenuate apomorphine-induced decrease in acoustic startle response in
rats suggesting an interaction between D1-NMDA receptors (Glass et al., 2013). Along
with behaviours mentioned above, D1-NMDA interactions were found to control higher
cognitive functions. Intra-medial dorsal striatum co-infusion of D1 and NMDA receptor
antagonists at respective ineffective dose significantly decreased accuracy of visual
discrimination in the 5 choice serial reaction time task (5CSRT) in rats (Agnoli and Carli,
2011). Moreover, Nai et al. (2010) reported that uncoupling of D1-NMDA receptor
interaction by using an interfering peptide (TAT-D1-t2 peptide) eliminates D1 receptorinduced upregulation of NMDA mediated LTP in rat hippocampal cultures. In addition to
this, in the same study, intra-hippocampal infusion of TAT-D1-t2 peptide impaired
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working memory in mice. Intra-mPFC infusion of D1 receptor agonist rescued setshifting in amphetamine-sensitized rats (Fletcher et al., 2005) suggesting D1-NMDA
interaction controlling behaviour.
From the aforementioned literature, it seems that there are strong interactions
between D1 and NMDA receptors regulating different types of behaviours in animals.
These behavioural findings were supported by number of electrophysiology studies
showing synergistic interaction between dopamine D1 and glutamate NMDA receptors.
Kruse et al. (2009) reported that, D1 receptors and NMDA receptors are co-localized in
single pyramidal neuron as well as GABA interneurons in the adult rat PFC. In the same
study, activation of D1 receptors was found to potentiate NMDA receptor mediated
increase in cytosolic calcium ions. Activation of D1 receptors upregulated NMDA
receptor-mediated LTP in the hippocampus, PFC or striatum (Calabresi et al., 2000;
Gurden et al., 2000; Kerr and Wickens, 2001; Nai et al., 2010). Furthermore, both D1 and
NMDA receptors potentiated each other’s expression at synaptic membrane in PFC and
striatum (Jay, 2003; Hallett et al., 2006; Scott et al., 2006; Castner and Williams, 2007;
Gao and Wolf, 2008).
Although interactions between D1-NMDA receptors are studied in detail, direct
evidence of role of this interaction regulating set-shifting is still to be understood.

Mechanisms underlying D1-NMDA interactions
From the above-mentioned studies, it seems that interactions between D1-NMDA
receptors are important. A number of studies investigated the mechanisms underpinning
D1-NMDA receptor interactions which are complex in nature. These interactions either
facilitate or inhibit responses to receptor activation (Cepeda and Levine, 2006).

D1-NMDA receptor interactions through protein kinase A
(PKA) signaling cascade
D1-NMDA receptor interactions have been reported to be mediated by number of
molecular signaling cascades in the PFC as well as the striatum (Kerr and Wickens, 2001;
Cepeda and Levine, 2006; Kruse et al., 2009). The most important is of D1 activated
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cAMP-PKA cascade which leads to a multitude of outcomes including phosphorylation
of NR1 subunits of NMDA receptors (Snyder et al., 1998) and activation of voltage-gated
Ca++ channels (Cepeda et al., 1998; Tseng and O’Donnell, 2004; Kruse et al., 2009). On
the other hand, antagonizing D1 receptors attenuated the PKA-mediated phosphorylation
of NR1 subunits (Edwards et al., 2002), and inhibiting PKA prevented D1-induced
NMDA-mediated calcium signaling (Kruse et al., 2009). Thus, PKA is an important
signaling molecule used by D1-NMDA receptor interactions. Table 1.1 summarizes D1NMDA interactions mediated through PKA cascade.

D1-NMDA receptor interactions through extracellular signalregulated kinase (ERK) signaling cascade
Sarantis et al. (2009) showed that combined treatment with sub-effective doses of
D1 agonist and NMDA in the mPFC or hippocampus slices caused an increase in
phosphorylation of NR1 and NR2B subunits of NMDA receptors. Interestingly, the
signaling pathway associated with the synergism involved phosphorylation of ERK1/2.
However, unlike what was described in the striatum, D1  ERK1/2 cascade is
independent of DARPP-32 as an intermediary in the PFC. In the same study, authors
stated the possibility of an involvement of PKA and protein kinase C (PKC) which would
activate ERK1/2 signaling pathway as reported previously by Cahill et al. (2014). In
agreement with the study of Sarantis et al. (2009), involvement of ERK1/2 signaling in
D1-NMDA interaction was also reported by others in the hippocampus and NAc
(Papadeas et al., 2004; Haberny and Carr, 2005; Sarantis et al., 2012).

Physical D1-NMDA receptor interactions
Direct physical interaction between D1 and NMDA receptors has also been
reported in hippocampal neuronal cultures, PFC and the striatum (Lee et al., 2002; Pei et
al., 2004; Hu et al., 2010; Groveman et al., 2012). Protein-protein interactions between Cterminals of D1 receptors and NMDA receptor subunits NR1 or NR2A allow direct
cross-talk between two receptors (Lee et al., 2002; Fiorentini et al., 2003; Pei et al.,
2004). Interaction of D1 with NR1 increases plasma membrane insertion of D1 receptors
upregulating D1 receptor function and this upregulation was found to be mediated
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through Fyn kinase, a family member of Src kinase, in PFC (Pei et al., 2004; Hu et al.,
2010). Table 1.1 summarizes D1-NMDA interactions mediated through direct proteinprotein interaction.
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Table 1.1 Summary of D1 and NMDA receptor interactions
Receptor
activated
Physical
interactions
NMDA

Preparation

Region

Effect

Mechanism

References

Organotypic
cultures

Striatum

D1 receptors
in spines

Scott et al., (2006)

NMDA

COS7, cell
cultures
HEK293, cell
cultures

Hippocampus

HEK293,
COS7, PSD

Striatum

D1 receptors
in membrane
NMDA
currents
Excitotoxicity
Translocation
of D1-NR1
D1 agonist–
induced
internalization

Allosteric
change,
diffusion trap
D1-NR1
binding
D1-NR2A
binding D1NR1 binding
Oligomerization
of D1 and NR1

Ca++-dependent

Scott et al., (2002)

Fyn protein
tyrosine kinase

(Dunah and
Standaert, 2001;
Fiorentini et al.,
2003)
(Cepeda et al.,
1992, 1998;
Snyder et al.,
1998; Wang and
O’Donnell, 2001;
Flores-Hernández
et al., 2002;
Seamans and
Yang, 2004;
Tseng and
O’Donnell, 2004)
(Chergui and
Lacey, 1999;
Chen et al., 2004)

D1

D1

Hippocampus

Pei et al., (2004)
Lee et al., (2002)

Fiorentini et al.,
(2003)

Second messenger–mediated interactions
NMDA

Cell cultures

Striatum

D1

Synaptosomes
from brain
slices

Striatum

D1 receptors
in spines
NR1, NR2A,
NR2B in
synaptosomes

D1 and
NMDA

Brain slices,
oocytes,
dissociated
cells

Striatum,
cortex

NMDA
responses

cAMP–PKA–
DARPP-32,
Ca++

D1 and
NMDA

Brain slices,
cells

N.
accumbens,
cortex

NMDA
responses

PKC, Ca++

Review Cepeda and Levine (2006)
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1.2 Thesis objectives and hypotheses
Based on the overview of the literature, deficits in the behavioural flexibility and
increased propensity of perseverative errors are core cognitive abnormalities in certain
CNS disorders, including, schizophrenia, and are associated with abnormal functioning of
interconnected brain areas, including the PFC. Post-mortem findings and previous animal
studies showed marked decreases of glutamate and dopamine levels in the PFC
individually and is sufficient to cause increased perseverative errors leading to
impairment in behavioural flexibility. However, recent in vivo imaging studies have
shown that, in living patients the loss of these neurotransmitters is minimal.
Consequently, our overall hypothesis was that the minimal loss of glutamate or
dopamine function is sufficient to produce impaired behavioural flexibility by
increased perseverative errors provided those losses co-occur in the brain. This also
suggests that there may by synergy between glutamate and dopamine neurotransmitter
abnormalities. In order to test our overall hypothesis, an operant conditioning-based setshifting paradigm was used. Following three studies were undertaken to test our overall
hypothesis and to elucidate associated molecular signaling mechanisms mediating
proposed synergy between deficiencies in neurotransmitter actions and how they are
relevant to behavioral flexibility.

Study I
The role of dopamine D1 and glutamate NMDA receptors is well-recognized in
the regulation of memory, cognition and executive functioning (Okubo et al., 1997;
Nieoullon, 2002; Volk et al., 2015; Thomas et al., 2017; Akil et al., 2013). Contrary to
the notion based on post-mortem studies, recent in vivo imaging studies have shown that
the changes in the dopamine and glutamate levels in the PFC of living schizophrenic
patients are very subtle (Laruelle et al., 2003; Théberge et al., 2007; Ohrmann et al.,
2007; Galińska et al., 2009; Rowland et al., 2009; Aoyama et al., 2011; Seese et al., 2011;
Szulc et al., 2011; Goto et al., 2012; Kegeles et al., 2012; Slifstein et al., 2015; Howes et
al., 2015). It is possible that these subtle alterations in neurotransmitter systems
ultimately result in noticeable cognitive impairments. In animal studies, the individual
role of dopamine and glutamate has been investigated in regulating set-shifting behaviour
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and results showed that large decreases in individual transmitters in different brain areas
could impair set-shifting performance (Stefani et al., 2003; Haluk and Floresco, 2009;
Tait et al., 2014; Gauthier et al., 2014). Functional neuroimaging studies have indicated
that a number of cortical and subcortical areas including dlPFC, anterior cingulate cortex,
striatum, hippocampus and the MDT are associated with successful performance of the
WCST (Stratta et al., 1997; Rüsch et al., 2007; Wilmsmeier et al., 2010; Pedersen et al.,
2012; Young et al., 2000; Kemether et al., 2003). In agreement with this, several animal
studies have shown that, inactivation of number of brain areas or connections among
them could lead to impaired set-shifting. Since, the hypothesized interaction between
dopamine-glutamate neurotransmitters could occur in several potential areas as shown in
animal studies (Block et al., 2007; Floresco et al., 2008; 2009), we decided to use
systemic route of drug administration to target brain circuitry rather than specific nuclei.
We tested effect of combined systemic administration of dopamine D1 and glutamate
NMDA receptor antagonists on set-shifting behaviour in normal rats.
The following is the specific aim of the study I:
To determine the effect of systemic combined administration of “behaviourally subeffective” doses of D1 and NMDA receptor antagonists on set-shifting in normal
rats.

Study II
Across species, PFC is associated with executive functioning (Abbruzzese et al.,
1996; Ragozzino et al., 199b; Floresco et al., 2008; Moore et al., 2009). Patients with
prefrontal pathology of schizophrenia or accidental frontal lobe damage show impaired
executive functions (Milner, 1963; Nelson, 1976; Smith and Jonides, 1999; Stuss and
Alexander, 2000; Stuss et al., 2000; Roca et al., 2010; Sira and Mateer, 2014). In clinical
studies, prefrontal cortical dopamine as well as glutamate neurotransmitters were
proposed to regulate cognition and abnormal functioning of these neurotransmitters may
impair cognition in schizophrenia (Krystal et al., 2000; Coyle, 2006; Akil et al., 2013). In
line with the clinical studies, findings from animal studies confirm essential role of
dopamine and glutamate neurotransmitters individually in the mPFC for normal
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executive functioning (Ragozzino, 2002a; Stefani and Moghaddam et al., 2003; Gauthier
et al 2014). In addition, several behaviours other than executive function, are regulated by
interaction between D1 and NMDA receptors (Smith-Roe and Kelley, 2000; Baldwin et
al., 2002; Fletcher et al., 2005; Nai et al., 2010; Agnoli and Carli, 2011; Touzani et al.,
2013; Glass et al., 2013).
From our first study, it was evident that the systemic combined administration of
behaviourally sub-effective doses of D1 and NMDA receptor antagonists caused setshifting impairments and produced error profile similar to inactivation or lesioning
studies in mPFC (Everett et al., 2001; Block et al., 2007; Floresco et al., 2008; Roca et
al., 2010). Therefore, we hypothesized that, PFC is one of the brain sites where
synergism between dopamine and glutamate abnormalities could occur. In the second
study, we sought to find out if the mPFC is associated with synergism between D1NMDA receptor antagonists. To test our hypothesis, we infused mPFC of normal rats
with D1 or NMDA receptor antagonists individually to determine their dose-response
profile in set-shifting. The highest but ineffective doses of these antagonists were then
combined to determine whether there is a synergism between them causing increased
perseverance in set-shifting.
The following is the specific aim of study II:
To determine the effect of intra-mPFC co-infusion of ‘behaviourally sub-effective’
doses of D1 and NMDA receptor antagonists on set-shifting in normal rats.

Study III
From the literature, it was evident that in different areas of the brain, interactions
between D1-NMDA receptors may use mainly three molecular signaling pathways: PKA,
ERK or direct protein-protein interactions between D1 and NMDA receptor complexes
through Fyn kinase. Interestingly, all main three pathways (PKA, ERK and Fyn kinase
mediated protein-protein interaction) have been implicated in the pathology of
schizophrenia (Tardito et al., 2001; Rybakowski et al., 2007; Yuan et al., 2010; Hahn,
2011; Kunii et al., 2011; Wang et al., 2015).
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In the mPFC, D1-NMDA receptors may interact via PKA signaling cascade to
regulate learning in rats (Baldwin et al., 2002). Furthermore, PKA was also found to
regulate synergistic effect of D1-NMDA receptors on excitability of pyramidal neuron in
the mPFC (Wang and O’Donnell, 2001). Along with PKA, ERK signaling was also found
to regulate D1-NMDA receptor interaction in the mPFC (Sarantis et al., 2009; Nagai et
al., 2007). Moreover, physical interaction between D1-NMDA receptors seems to
potentiate each other’s function (Gao and Wolf, 2008; Hu et al., 2010).
From results obtained in the study II, it appears that mPFC is one of the nuclei
where D1-NMDA receptors are interacting with each other to regulate set-shifting
behaviour. Thus, we hypothesized that molecular mechanisms underlying D1-NMDA
receptor interaction will use one or more of the following pathways in mPFC neurons to
regulate set-shifting behaviour: a) PKA b) ERK1/2 c) Fyn kinase-mediated interaction
between D1-NMDA receptors. To test our hypothesis, we performed a series of the
following experiments: a) effects of elevating PKA levels in the mPFC in animals
receiving intra mPFC infusion of a combination of D1 and NMDA antagonists that
disrupted set-shifting performance in study II; b) effects of inhibiting ERK1/2
phosphorylation on set-shifting performance in naïve rats; and c) effect of inhibiting Fyn
kinase in the mPFC on set-shifting behaviour.
Following specific aims were tested in this study:
1. To determine the effect of elevating PKA in the mPFC on D1-NMDA receptor
antagonist combination (from study II)-induced impaired set-shifting.
2. To determine the effect of inhibiting Fyn kinase and hence to verify if direct D1
 NMDA receptor cross-talk facilitates set-shifting in normal rats.
3. To determine the effect of inhibiting ERK1/2-phosphorylation in the mPFC using
MAPK (mitogen-activated protein kinase) inhibitors on set-shifting in normal
rats.
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Combination of behaviourally sub-effective doses of
glutamate NMDA and dopamine D1 receptor antagonists
impairs executive function1
2.1 Abstract
Impairment of executive function is a core feature of schizophrenia. Preclinical
studies indicate that injections of either N-methyl D-aspartate (NMDA) or dopamine D1
receptor blockers impair executive function. Despite the prevailing notion based on postmortem findings in schizophrenia that cortical areas have marked suppression of
glutamate and dopamine, recent in vivo imaging studies suggest that abnormalities of
these neurotransmitters in living patients may be quite subtle. Thus, we hypothesized that
modest impairments in both glutamate and dopamine function can act synergistically to
cause executive dysfunction. In the present study, we investigated the effect of combined
administration of “behaviourally sub-effective” doses of NMDA and dopamine D1
receptor antagonists on executive function. An operant conditioning-based set-shifting
task was used to assess behavioural flexibility in rats that were systemically injected with
NMDA and dopamine D1 receptor antagonists individually or in combination prior to
task performance. Separate injections of the NMDA receptor antagonist, MK-801, and
the dopamine D1 receptor antagonist, SCH 23390, at low doses did not impair setshifting; however, the combined administration of these same behaviourally sub-effective
doses of the antagonists significantly impaired the performance during set-shifting
without affecting learning, retrieval of the memory of the initial rule, latency of responses
or the number of omissions. The combined treatment also produced an increased number
of perseverative errors. Our results indicate that NMDA and D1 receptor blockade act
synergistically to cause behavioural inflexibility, and as such, subtle abnormalities in
glutamatergic and dopaminergic systems may act cooperatively to cause deficits in
executive function.

1

Chapter 2 has been published as: Desai SJ, Allman BL, Rajakumar N (2017)
Combination of behaviourally sub-effective doses of glutamate NMDA and dopamine D1
receptor antagonists impairs executive function. Behav Brain Res 323:24-31.
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2.2 Introduction
Executive function is a complex phenomenon comprising attention, working
memory, planning, reasoning, sequencing, inhibitory control and cognitive flexibility
(Robbins et al., 1996). Severe impairment of executive function is a core feature of
schizophrenia, and is an important determinant of long-term outcome and quality of life
of these patients (Hutton et al., 1998; Krieger et al., 2005; Holthausen et al., 2007;
Penadés et al., 2010). In addition to challenges with daily activities, patients with
impaired executive function demonstrate difficulty performing standardized
neuropsychological assessments of behavioural flexibility, such as the Wisconsin card
sorting test (WCST) (Anderson et al., 1991; Prentice et al., 2008). Based on the findings
from functional neuroimaging studies, a variety of cortical and subcortical areas have
been implicated in the successful performance of the WCST, most notably the
dorsolateral prefrontal cortex (dlPFC) anterior cingulate cortex, striatum, hippocampus
and the mediodorsal nucleus of the thalamus (MDT) (Stratta et al., 1997; Rüsch et al.,
2007; Wilmsmeier et al., 2010; Pedersen et al., 2012). Similarly, preclinical studies in
rodents have confirmed that the aforementioned brain regions are necessary for
behavioural flexibility during such tasks as set-shifting (Ragozzino et al., 1999;
Ragozzino et al., 2002; Block et al., 2007; Floresco et al., 2008, 2009; Haluk and
Floresco, 2009).
Post-mortem studies on schizophrenic brains have demonstrated a significant loss
of glutamic acid decarboxylase-67 (GAD67) expression across multiple cortical areas
indicating decreased activity of -amino butyric acid (GABA) (Woo et al., 1998;
Hashimoto et al., 2003; Ishikawa et al., 2004; Duncan et al., 2010). Furthermore, a
marked loss of dopaminergic fibers was described in the dlPFC of post-mortem brains of
schizophrenia (Knable and Weinberger, 1997; Akil et al., 1999), and there was a severe
loss of dendritic spines within the prefrontal cortex and the hippocampus, indicating
possible loss of glutamatergic synapses in schizophrenia (Glantz and Lewis, 2000).
Decreased levels of a number of proteins associated with glutamatergic synapses in the
thalamus were also identified (Clinton and Meador-Woodruff, 2004). In addition, a
significant loss of neurons has been described in the mediodorsal nucleus of the thalamus
in schizophrenia brains (Galińska et al., 2009). Overall, available post-mortem studies of
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schizophrenia, despite the heterogeneity of the disorder, point to a severe loss of
glutamatergic, dopaminergic and GABAergic function in multiple brain areas in
schizophrenia. Consistent with the findings, preclinical studies using set-shifting tasks
have revealed that the separate administration of relatively high doses of either D1
dopamine, N-methyl D-aspartate (NMDA) or GABA-A receptor antagonists worsens
performance (Stefani and Moghaddam, 2005; Enomoto et al., 2011; Floresco, 2013;
Nikiforuk et al., 2016), suggesting that decreased activity of any one of these
neurotransmitters could underlie the impaired behavioural flexibility in schizophrenia.
Although the collective results of post-mortem studies on schizophrenia brains
and preclinical models suggest that severe deficits in GABA, dopamine or glutamate
function may be responsible for the impairments in executive function observed in
schizophrenia, the results of in vivo imaging studies on schizophrenic patients
consistently provide a contradictory view. Studies using in vivo magnetic resonance
spectroscopy (MRS) or positron emission tomography (PET) have identified that levels
of glutamate, dopamine and GABA in the dlPFC and thalamus are not different or
slightly altered in schizophrenia patients in comparison to control groups (Théberge et al.,
2007; Ohrmann et al., 2007; Galińska et al., 2009; Rowland et al., 2009; Aoyama et al.,
2011; Seese et al., 2011; Szulc et al., 2011; Goto et al., 2012; Kegeles et al., 2012;
Frankle et al., 2015; Slifstein et al., 2015). Based on the above MRS and PET findings, it
is conceivable that the extent of suppression of neurotransmitter function predicted based
on post-mortem findings may not apply in patients living with schizophrenia, and if at all,
the differences may be subtle, perhaps due to compensatory mechanisms. Furthermore,
recent theories postulate that certain GABA abnormalities in schizophrenia might be
compensatory (Gonzalez-Burgos et al., 2011; Lewis, 2014). Consequently, we
hypothesized that subtle abnormalities in the glutamate and dopamine neurotransmitter
systems in functionally-connected cortical and subcortical areas may cooperate
synergistically to impair executive function in schizophrenia; an experimental
consideration which had not been addressed in previous preclinical rodent models as they
only targeted a single neurotransmitter system at a given time.

53

Among dopamine receptors, D1 receptor subtype is more commonly implicated in
executive function (Duncan et al., 2010; Szulc et al., 2011). In addition, in vivo imaging
studies have identified increased D1 receptor levels in the dlPFC in schizophrenia
patients (Ozonoff et al., 2004). Consequently, in the present study, we focused on D1
receptor antagonism. Ultimately, we investigated the potential synergistic effect of the
combined administration of “behaviourally sub-effective” doses of D1 and NMDA
receptor antagonists on set-shifting in rats performing a lever-pressing task that required
them to shift between visual-cue and egocentric spatial response-based discrimination
strategies according to the paradigm of Enomoto et al. (2011). To that end, in separate
groups of rats, we first determined the doses of the D1 antagonist, SCH 23390, and
NMDA uncompetitive antagonist, MK-801, which when systemically administered
alone, failed to worsen set-shifting performance compared to vehicle-treated controls.
Next, these behaviourally sub-effective doses were co-administered systemically to a
separate group of rats, and the results compared to controls as well as rats that received a
higher (i.e., “effective”) dose of MK-801 delivered alone.

2.3 Materials and methods
Animals
Adult male Sprague Dawley rats (Charles River, Quebec, Canada) weighing 325350 g at the beginning of the study were housed individually in an animal facility with
temperature and humidity controlled rooms (24±2 °C, relative humidity 55±10%), 12 h
light/dark cycle (lights on at 7:00 am). Animals were food restricted to ~85% of their free
feeding body weight. During food restriction, rats were weighed and handled for several
minutes per day to get familiarized to handling by the investigator. All procedures were
approved by the Institutional Animal Care Committee and followed the Canadian and
National Institute of Health Guides for the Care and Use of Laboratory Animals (NIH
Publication #80-23).

Drugs
The glutamate NMDA receptor antagonist MK-801 [(+)-MK-801 maleate, MWt:
337; (dizocilpine); 0.075 mg/kg or 0.05 mg/kg of the salt form; Sigma-Aldrich, St.
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Louise, MO], and dopamine D1 antagonist SCH 23390 [(R)-(+)-SCH 23390
hydrochloride, MWt: 324; 0.005 mg/kg of the salt form; Sigma-Aldrich] were used, with
the doses chosen based on pilot studies. Despite a small difference in concentration (0.18
on a Log10 scale), 0.075 mg/kg of MK-801 consistently affected set-shifting compared to
0.05 mg/kg dose in pilot studies. Thus, in the present study, these doses of MK-801 were
employed and referred to as “effective” and “behaviourally sub-effective” doses,
respectively. Drugs were freshly prepared and dissolved in physiological saline. Rats
received subcutaneous injections of drugs individually or in combination on the day of
response discrimination (i.e., set-shifting), 25 min prior to the visual-cue retrieval trials.
In pilot studies, higher doses of SCH 23390 resulted in gross motor deficits, which
rendered animals incapable of performing the visual-cue and set-shifting tasks, and
therefore, experiments using these higher doses of SCH 23390 were not included in the
present study.

Apparatus
The operant conditioning apparatus (Med-Associates, St. Albans, VT, USA)
consisted of a modular acrylic test chamber (30.5 X 24 X 21 cm), housed in a soundattenuating box. The test chamber was equipped with grid floor, two retractable levers on
either side of a central pellet receptacle, and a house light (white, 100-mA, located
centrally on the top of the wall opposite to the levers). Positioned above each lever was a
cue light (light emitting diode). Following a lever-press that was considered a correct
response, a pellet dispenser dropped a sucrose pellet (45 mg; BioServ, Frenchtown, NJ)
into the central pellet receptacle. The operation of the chamber was controlled by a
customized computer software program (MED-PC IV, Med-Associates).

Set-shifting
Behavioural flexibility was assessed in rats using an operant conditioning-based a
set-shifting task developed by Floresco et al. (2008), with minor modifications. As
described in detail below, rats were exposed to a series of experimental steps which
included acclimatization to the chamber, training to press the levers, determination of the
rat’s preference for one lever over the other (i.e., its side bias), visual-cue discrimination
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ability, and finally, response discrimination ability to assess behavioural flexibility. Each
rat completed this entire series of experimental steps only once.

2.3.4.1 Acclimatization
Rats were given 10 sucrose pellets in their home cage a day before their first
exposure to the operant chamber. On the acclimatization day, rats were given 3 sucrose
pellets in the receptacle as well as 3 crushed pellets were placed on the extended lever.
Once the rat learned the relationship between lever-pressing and reinforcement, it had to
achieve the criterion of 30 lever presses in 50 min. Once achieved, the second lever was
inserted into the chamber, and the first lever was retracted. After achieving the
performance criterion for both levers, rats were ready for the training procedure (Please
see Figure 2.1 for timeline of experiments).

2.3.4.2 Training
On the training day, a trial began with illumination of the house light, and the
random insertion of one of the retracted levers into the chamber. Rats were given 10 s to
respond on the extended lever. If the rat pressed the extended lever, a sucrose pellet
(reinforcement) was dispensed in the central receptacle, and the house light remained on
for an additional 4 s (reward length). If the rat failed to respond within 10 s, the house
light was turned off, the lever was retracted without pellet reinforcement, and the trial
was counted as an omission. Each training trial lasted 20 s. Over a total of 90 successive
trials, each of the levers was randomly inserted into the chamber, and the performance
criterion set was less than 5 omissions.

2.3.4.3 Side bias determination
Once the rats achieved the criterion for the training session, their side bias was
determined on the same day. A side bias trial began with the illumination of the house
light and the insertion of both levers into the chamber. Rats were given 10 s to respond on
either of the levers. Upon pressing one of the levers, both levers were then retracted, a
pellet reinforcement was delivered, and the house light remained on for an additional 4 s
before the chamber went dark. If the rat failed to respond within 10 s, the house light was
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turned off, the levers were retracted without pellet reinforcement, and the trial was
counted as an omission. The next trial began with the illumination of the house light and
the insertion of both levers into the chamber, but this time the rat was given 10 s to
respond on the lever opposite to its initial choice. If rat responded correctly, a pellet
reinforcement was given. If rat pressed the wrong (i.e, initial) lever, both levers were
retracted, reinforcement was not delivered, and the chamber went dark. This continued
until rat responded on correct lever. In total, seven complete trials were conducted (i.e.,
initial choice and correct second choice). For each rat, the lever that was pressed as the
initial choice more often was considered its side bias. This preference was acknowledged
on the response discrimination day (set-shift day), where the lever opposite to the rat’s
side bias was always considered the correct lever.

2.3.4.4 Visual-cue discrimination
On the day following training and side bias determination, rats were subjected to a
visual-cue discrimination task where they had to follow the cue light as a strategy to
receive pellet reinforcement. A trial started with random illumination of one of the cue
lights. After 3 s, the house light was turned on, and both the levers were extended into the
chamber. The rat was given 10 s to respond on the lever positioned under the illuminated
cue light. If the rat chose the correct lever, a pellet reinforcement was offered, both levers
were retracted, the house light remained on for 4 s, and the trial was counted as a correct
response. Pressing the wrong lever resulted in retraction of both levers, no pellet
reinforcement being offered, and the chamber going dark. The performance criterion
established for visual-cue discrimination was 10 consecutive correct responses, and the
maximum number of trials performed was 100. We modified the original procedure
developed by Floresco et al. (2008) by having all rats complete 100 trials instead of
ending the session at the moment when a given rat achieved the performance criterion.

2.3.4.5 Response discrimination
On the day after visual-cue discrimination, rats were injected with drugs or
vehicle in their home cage, and 25 min later, they were subjected to 20 visual-cue
discrimination trials to determine the effect of drug treatments on retrieval of the memory
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and motor function to perform the expected task. On the 21st trial, the paradigm was
switched from a visual-cue discrimination to a response discrimination, in which the rats
had to abandon the original rule (i.e., follow the cue light) and adopt a new rule which
was previously irrelevant (i.e., lever side). During set-shifting, rats had to respond on the
lever opposite to their side bias during every trial regardless of the location of the visualcue. A trial started with random illumination of one of the visual-cue lights. After 3 s, the
house light turned on, both levers were extended into the chamber, and the rat was given
10 s to respond on the lever opposite to its side bias. If the rat responded on the correct
lever, a pellet reinforcement was delivered, both levers were retracted, the house light
stayed for an additional 4 s, and the trial was counted as a correct response. Pressing the
wrong lever was counted as an error, resulting in retraction of both levers, no pellet
reinforcement being offered, and the chamber going dark. The response discrimination
session ended when either the rat made 10 consecutive correct responses or if the
maximum number of 120 trials was performed. Total number of trials taken and errors
committed to achieve criterion were recorded.

2.3.4.6 Error analysis
Errors committed during set-shifting (response discrimination) were divided into
three different categories according to Floresco et al. (2008): perseverative error,
regressive error and never-reinforced error. An error was called “perseverative” or
“regressive” if during the set-shifting, the rat responded on the lever associated with
visual-cue light when it was required to press the opposite lever to receive the pellet
reinforcement. In a block of 16 trials, 8 of the trials required the rat to respond on the
lever opposite to the visual-cue light. During those 8 trials, if the rat committed errors by
pressing the lever associated with visual-cue light in 6 or more trials, all the errors
committed in that block were considered “perseverative” errors. In contrast, if the rat
made the same error in 5 or less number of trials, now all of these errors in the particular
block were referred to as “regressive” errors. A “never-reinforced error” occurred during
a trial when the visual-cue light was associated with the correct lever, yet the rat
responded on opposite lever; a situation that had never been positively reinforced in
either the visual-cue or response discrimination task.
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2.3.4.7 Possible effect of combined drug treatment on learning
A separate experimental series was conducted on naïve rats in order to determine
whether the combined treatment of MK-801 (0.05 mg/kg) and SCH 23390 (0.005 mg/kg)
affected learning of a given lever-pressing rule, as opposed to actual set-shifting. One day
after being trained to press the levers, these rats (n=5 per group) were administered
systemically with either vehicle (saline) or the combined treatment of MK-801 (0.05
mg/kg) and SCH 23390 (0.005 mg/kg), and 25 min later, tested on their ability to learn
the visual-cue discrimination task. Because this was the first time that these rats had been
exposed to the visual-cue discrimination task, this experiment would determine if the
combined administration of the behaviourally sub-effective doses of MK-801 and SCH
23390 caused a general inability to learn a lever-pressing rule, separate from the
behavioural flexibility necessary to perform set-shifting. These rats did not go on to
perform a subsequent response discrimination (i.e., set-shifting) experiment the next day.

Statistical analysis
All animals included in the analysis of response discrimination showed
comparable performance in visual-cue discrimination on the previous day to ensure
similar baseline function. A one-way analysis of variance (ANOVA) was employed to
compare effect of drug treatments on visual-cue retrieval, trials and errors to criteria, and
number of omissions. For type of errors and latency, a two-way mixed ANOVA was
used. Results of visual-cue learning was analyzed using student’s two-tailed t-test. All
statistical analyses were conducted with  = 0.05 using GraphPad Prism 7.0 software.
Following ANOVA, significant values were further analyzed using the Tukey’s post hoc
test. All data are presented as mean  standard error of mean (SEM).
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Figure 2.1 Timeline of set-shifting task.
Following handling and acclimatization to the chamber, the rats were subjected to
training. Once the rats achieved the criterion for the training session, their side bias
was determined on the final day of training. On the next day, rats were subjected to
visual-cue discrimination, and the following day was the response discrimination (setshifting) test. On the response discrimination day, the rats were injected with drugs or
vehicle, and 25 min later, they were subjected to 20 visual-cue discrimination trials to
determine the effect of drug treatments on retrieval of the memory and motor function.
On the 21st trial, the paradigm was switched from a visual-cue discrimination to a
response discrimination that lasted until either the rat made 10 consecutive correct
responses or to the maximum number of 120 trials.
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2.4 Results
Effect of MK-801, SCH 23390 or combined drug treatment on
visual-cue retrieval
In order to determine whether administration of MK-801 and/or SCH 23390
produced any noticeable effect on memory retrieval or motor performance, rats were
subjected to 20 trials of visual-cue discrimination just prior to the response discrimination
(i.e., set-shifting) trials. Results showed that none of the drugs at the chosen doses
affected the performance of visual-cue retrieval on the day of response discrimination
(Figure 2.2; P>0.05, One-way ANOVA).

Figure 2.2 Effect of systemic administration of individual or combined antagonists on
visual-cue retrieval on set-shift day.
On the set-shift day (response discrimination day), treatment with MK-801(0.05 or 0.075
mg/kg; s.c.), SCH 23390 (0.005 mg/kg; s.c.) or the combination of MK-801 (0.05 mg/kg;
s.c.) and SCH 23390 (0.005 mg/kg; s.c.) did not affect visual-cue retrieval indexed by the
unchanged number of errors committed during the first 20 visual-cue trials as compared to
the vehicle group (P>0.05, One-way ANOVA).
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Effect of MK-801, SCH 23390 or combined drug treatment on setshifting
2.4.2.1 Number of trials to criterion
Rats were administered with individual antagonists (n=7, each group) or a
combination of behaviourally sub-effective doses of antagonists (n=7) 25 min prior to the
visual-cue retrieval trials on the day of the set-shifting test. Injections of MK-801 (0.075
mg/kg; s.c.) significantly increased the total number of trials to criterion
[F(4,30) = 15.80, P<0.05] compared to the vehicle-treated group (Figure 2.3; one-way
ANOVA followed by the Tukey’s post hoc test). Thus, the 0.075 mg/kg dose of MK-801
when administered systemically, significantly impaired set-shifting in rats. On the other
hand, MK-801 at the lower dose tested (0.05 mg/kg; s.c.) did not show any change in the
number of trials to criterion (P>0.05), and therefore, this dose was considered to be
“behaviourally sub-effective.” Similarly, SCH 23390 (0.005 mg/kg) did not significantly
affect trials to criterion as compared to the vehicle-treated group (P>0.05), hence, this
dose was deemed to be behaviourally sub-effective. In pilot studies, rats that received
higher doses of SCH 23390 (0.01 or 0.02 mg/kg; s.c.) experienced noticeable motor
deficits and increased response latency, which resulted in a significant number of
omissions in both the visual-cue retrieval and set-shifting trials, and ultimately a failure to
complete the sessions (data not shown).
Administration of a combination of the behaviourally sub-effective doses of MK801 (0.05 mg/kg; s.c.) and SCH 23390 (0.005 mg/kg; s.c.) significantly increased the
number of trials to criterion [F(4,30) = 15.80, P<0.05]. Tukey’s post hoc test revealed
that the combined treatment increased the number of trials to criterion significantly more
than vehicle treatment as well as the separate injections of the behaviourally sub-effective
doses of MK-801or SCH 23390 (P<0.05). Interestingly, the effective (higher) dose MK801 (0.075 mg/kg; s.c.) group did not differ from the group that received the combined
treatment of behaviourally sub-effective doses of MK-801 and SCH 23390 in the number
of trials to criterion (P>0.05).
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Figure 2.3 Effect of systemic administration of individual or combined antagonists
on trials to criterion during set-shifting.
Low dose MK-801 (0.05 mg/kg; s.c.) or SCH 23390 (0.005 mg/kg; s.c.) did not affect the
number of trials to criterion as compared to the vehicle group (P>0.05), and as such,
these doses were considered to be “behaviourally sub-effective.” Alternatively, the

higher dose MK-801(0.075 mg/kg; s.c.) significantly increased the number of trials to
criterion during set-shifting as compared to the vehicle, low dose MK-801 (0.05 mg/kg;
s.c.), and SCH 23390 (0.005 mg/kg; s.c.) groups (*P<0.05). Consistent with our working
hypothesis, the combined administration of the behaviourally sub-effective doses of MK801 (0.05 mg/kg; s.c.) and SCH 23390 (0.005 mg/kg; s.c.) significantly increased the
number of trials to criterion as compared to the vehicle group and the individual
treatment groups of either low dose MK-801 (0.05 mg/kg; s.c.) or SCH 23390 (0.005
mg/kg; s.c.) (*P<0.05). Finally, the combined antagonist treatment group did not show
significant change in the number of trials to criterion as compared to the higher dose
MK-801 (0.075 mg/kg; s.c.) group (P>0.05). [One-way ANOVA followed by Tukey’s
post hoc test].
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2.4.2.1 Number of errors to criterion
Injections of MK-801 (0.075 mg/kg; s.c.) significantly increased the total number
of errors committed during the set-shifting [F(4,30) = 14.67, P<0.05] as compared to the
vehicle-treated group (Figure 2.4; one-way ANOVA followed by the Tukey’s post hoc
test). On the other hand, lower dose of MK-801 (0.05 mg/kg; s.c.) did not affect errors to
criterion P>0.05. Likewise, SCH 23390 (0.005 mg/kg) did not significantly influence
number of errors committed during the set-shifting as compared to the vehicle-treated
group (P>0.05), hence, this dose was considered to be “behaviourally sub-effective”.
Combined administration of behaviourally sub-effective doses MK-801 (0.05
mg/kg; s.c.) + SCH 23390 (0.005 mg/kg) significantly increased number of errors
committed during set-shifting [F(4,30) = 14.67, P<0.05]. Tukey’s post hoc analysis
showed a significantly increased (P<0.05) number of errors to criterion following the
combined treatment in comparison to vehicle treatment or separate antagonist injections.
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Figure 2.4 Effect of systemic administration of individual or combined antagonists on
errors to criterion during set-shifting.
Similar to the trials to criterion, the number of associated errors made during the setshifting session showed comparable treatment effects. As predicted, the number of errors
to criterion was found to be increased significantly following the combined administration
of MK-801 (0.05 mg/kg) and SCH 23390 (0.005 mg/kg) as compared to the vehicle group
and the individual treatment groups of either MK-801 (0.05 mg/kg) or SCH 23390 (0.005
mg/kg) (*P<0.05). In contrast, the combined antagonist treatment group did not show
significant change in the number of errors to criterion as compared to the higher dose MK801 (0.075 mg/kg) group (P>0.05). Consistent with the combined antagonist treatment
group, the higher dose MK-801 (0.075 mg/kg) treatment significantly increased the
number of errors committed during the set-shifting session as compared to the vehicle,
low dose MK-801 (0.05 mg/kg) or SCH 23390 (0.005 mg/kg) group (*P<0.05). [One-way
ANOVA followed by Tukey’s post hoc test].
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2.4.2.2 Type of errors
In accordance with Floresco et al. (2008), the errors committed during set-shifting
trials were classified into three different types: perseverative, regressive and neverreinforced (see Methods for details). Errors were analyzed using two-way mixed
ANOVA, as described previously in studies using a similar paradigm (Bornstein et al.,
1990; Ishikawa et al., 2004; Szoke et al., 2008). Whenever significant interactions
between the treatment conditions and the type of errors were found, the data were further
analyzed using Tukey’s post hoc test. Significant effects were observed for perseverative
errors in the between-subject factor (treatment) [F(4,24) = 16.94, P<0.05] as well as
within-subject factor (type of errors) [F(2,12) = 113.3, P<0.05]. Tukey’s post hoc test
revealed a significant difference (P<0.05) between perseverative errors committed by the
group treated with combination of antagonists versus the control group, low dose MK801 (0.05 mg/kg) or SCH 23390 (0.005 mg/kg). A significant interaction between
treatment X type of errors was also observed [F(8,48) = 2.36, P<0.05] (Figure 2.5). The
number of perseverative errors committed by the combined treatment group and effective
(higher) dose MK-801 (0.075 mg/kg; s.c.) group were not significantly different
(P>0.05). Compared to the control group, none of the treatments affected regressive or
never-reinforced errors (P>0.05).
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Figure 2.5 Effect of drug treatments on different type of errors committed during setshifting.
The combined administration of the behaviorally sub-effective doses of MK-801 (0.05 mg/kg) and
SCH 23390 (0.005 mg/kg) resulted in a significant increase in the number of perseverative errors
as compared to the vehicle group and the individual treatment groups of either MK-801 (0.05
mg/kg) or SCH 23390 (0.005 mg/kg) (*P<0.05). Similarly, the higher dose MK-801 (0.075
mg/kg) treatment significantly increased perseverative errors as compared to the vehicle, low dose
MK-801 (0.05 mg/kg) or SCH 23390 (0.005 mg/kg) groups (*P<0.05). Animals that received the
combined antagonist treatment did not differ significantly from higher dose MK-801 (0.075
mg/kg) treated rats in any type of error (P>0.05). Finally, none of the treatments significantly
increased the number of regressive or never-reinforced errors beyond those made by the vehicle
group. All drugs were administered s.c. [two-way mixed ANOVA followed by Tukey’s post hoc
test].
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Response latencies
Because our pilot studies using higher doses of SCH 23390 (0.01 or 0.02 mg/kg;
s.c.) revealed noticeable motor deficits that ultimately impaired performance, in the
present study we compared the latencies of response on the extended levers for last 5
trials of the different trial types: i) correct response on non-perseverative trials, ii) correct
response on trials where a perseverative error was possible, and iii) perseverative error
trials. A two-way ANOVA revealed that latencies for all the groups were similar for all
three trial types (P>0.05) (Figure 2.6). These data suggest that motor function was not
affected by the various treatments.

Omissions
The number of omissions made during response discrimination trials was
determined for all of the groups. Occurrence of omissions was negligible in all the groups
tested (P>0.05; One-way ANOVA) (Figure 2.6).

Figure 2.6 Effect of drug treatments on latencies to response during different types of
trials.
During each trial, animals were given 10 s to press one of the extended levers. As compared
to the vehicle group (P>0.05; Two-way ANOVA), none of the treatments showed significant
change in latencies to response during the various trial types: i) Correct non-perseverative: A
correct choice on a trial where there is no possibility of making a perseverative error; ii)
Correct perseverative chance: A correct response on a trial where a perseverative error is
possible; and iii) Perseverative error: An incorrect choice on a trial where a perseverative
error is possible. All drugs were administered s.c. in mg/kg doses as shown.
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Omissions
A one-way ANOVA revealed that number of omissions committed during setshifting were comparable across all the groups (P>0.05) (Figure 2.7). These data suggest
that motor function was not affected by the various treatments.

Figure 2.7 Effect of drug treatments on number of omissions committed during
set-shifting.

None of the treatments significantly changed the number of omissions committed
during set-shifting as compared to the vehicle group (P>0.05; One-way ANOVA). All
drugs were administered s.c. in mg/kg doses as shown.
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2.5 Discussion
The main finding of the present study was that the combined systemic
administration of relatively low doses of glutamate NMDA and dopamine D1 receptor
antagonists which were found to be ineffective at altering behavioural performance when
injected separately caused a significant impairment in set-shifting in rats performing an
operant conditioning-based task. To our knowledge, this is the first pharmacological
evidence of an interaction between glutamate and dopamine systems in regulating
executive function.
Our results also showed that the impairment of set-shifting ability produced by the
combination of behaviourally sub-effective doses of NMDA and D1 antagonists is
associated with increased perseverative errors, whereas the occurrence of regressive or
never-reinforced errors was unaffected. Perseverative errors occur when participants
cannot disengage from their adherence to a previously correct rule, despite prompt
negative feedback that a new strategy is warranted. Previous preclinical models have
shown that inactivation of the mPFC or mediodorsal thalamus results in increased
perseverative errors (Block et al., 2007; Floresco et al., 2008; Parnaudeau et al., 2015).
On the contrary, regressive errors occur after participants have been able to temporarily
disengage from the now-incorrect rule/strategy, yet they are unable to maintain the new
strategy despite receiving positive feedback. Unlike perseveration, inactivation of brain
structures including the striatum and nucleus accumbens core have been shown to cause
increased regressive errors (Block et al., 2007; Floresco et al., 2009). Perseverative errors
may result from failure in high-order cognitive flexibility, whereas regressive errors may
result from deficits in sustained attention (Sullivan and Faust, 1993; Hughes et al., 1997;
Russell et al., 1999; Ozonoff et al., 2004).
Increased perseverative error is a consistent finding in schizophrenia patients
performing the WCST (Bornstein et al., 1990; Szoke et al., 2008; Waford and Lewine,
2010), and it was also proposed as an endophenotype as unaffected siblings of
schizophrenia patients show high degree of perseverative errors in the WCST (Saoud et
al., 2000). Evidence, however, indicates that increased number of perseverative errors in
the WCST is also seen in non-psychotic patients diagnosed with bipolar disorder, major
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depression or autism (Rempfer et al., 2006; Griebling et al., 2010; Waford and Lewine,
2010; Landry and Al-Taie, 2016). Our results show that a combined systemic
administration of NMDA and D1 receptor blockers, at doses that do not cause
behavioural effects when these antagonists were administered separately, results in
increased incidence of perseverative errors. Based on the findings in the present study, it
is reasonable to suggest that subtle functional decreases in glutamate and dopamine
neurotransmission in circuits sub-serving successful performance of the WCST may act
cooperatively to manifest perseverative errors in the above-listed neuropsychiatric
disorders.
Interestingly, the extent of impairment and error profile seen following systemic
administration of behaviourally sub-effective doses of NMDA and D1 antagonists are
similar to that seen following administration of the effective (higher) dose of MK-801.
This may suggest that the addition of the D1 antagonist may exacerbate the NMDA
functional deficit in certain brain circuitries. It is also important to note that although
SCH 23390 has been shown to block dopamine D5 and serotonin 5HT2A receptors, the
dose of SCH 23390 used in the present study may have blocked D5 receptors but not
5HT2A (Suhara et al., 1992; Emmi et al., 1997). Interactions between NMDA receptors
and D1 receptors has been described in several brain areas (Greengard, 2001; Chen et al.,
2004; Tong and Gibb, 2008; Wigestrand et al., 2012). Acting on the same postsynaptic
profile, dopamine affects the second messenger systems and protein phosphorylation
through D1 receptors to facilitate NMDA receptor function (Greengard, 2001). In
addition, a direct receptor-receptor interaction also has been observed between NMDA
and D1 receptors in the rat (Lee et al., 2002; Martina and Bergeron, 2008). More
importantly, a recent study found that SCH 23390 induced a dose-dependent decrease of
[3H]MK-801 binding to membranes from rat hippocampus indicating a direct interaction
between SCH 23390 and MK-801 (Wigestrand et al., 2012). Considering that increased
perseverative errors have been observed following manipulation of either the mPFC,
mediodorsal thalamus or hippocampus (Block et al., 2007; Enomoto et al., 2011; Shaw et
al., 2012), and the present study used systemic injections of antagonists, it is possible that
the interaction between NMDA and D1 receptors indicated by our results may not
necessarily occur in the same neuron or even in the same brain area. Further studies are
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needed to identify the precise brain regions and neuronal connections where relatively
low doses of MK-801 and SCH 23390 exert their actions to cause perseverative errors. It
is also possible that these antagonists might have affected different components of
executive function to certain degree and these effects when combined become sufficient
to affect the set-shifting performance.
Previous preclinical studies have shown that direct infusion of either dopamine
D1 or NMDA receptor antagonists into the mPFC in rats resulted in disrupted set-shifting
and increased perseverative errors (Stefani et al., 2003; Fletcher et al., 2005; Floresco et
al., 2006). Similar to the mPFC, dopamine D1 receptor activity in the core region of the
nucleus accumbens has been found to be essential for set-shifting (Floresco et al., 2009;
Haluk and Floresco, 2009). Pharmacological or designer receptors exclusively activated
by designer drugs (DREADD)-mediated inactivation of mediodorsal thalamic nuclei that
send reciprocal glutamatergic projections to the prefrontal cortex resulted in impaired setshifting and increased occurrence of perseverative errors (Block et al., 2007; Parnaudeau
et al., 2015) indicating a potentially important role for glutamatergic activity in the
mediodorsal thalamus and its prefrontal cortical connection in executive function. As
mentioned, abnormalities in the prefrontal cortex, nucleus accumbens and the
mediodorsal thalamus are consistently reported in post-mortem and in vivo imaging
studies of schizophrenia. Consequently, we elected to use systemic injections to
antagonize D1 and/or NMDA receptors. Despite sacrificing brain regional specificity for
the site of action of these antagonists, our approach allowed us to assay several brain
areas that are not only relevant to executive function but also might have abnormalities in
dopamine D1 and NMDA receptor function contributing to executive functional deficits
of schizophrenia. Overall, our choice to use systemic injections of the D1 and NMDA
receptor antagonists in the present study is consistent with comments made in a review by
Floresco et al. (2009), which stated that, “…a more complete understanding of the
mechanisms underlying impaired flexibility in schizophrenia may be obtained from the
elucidation of dysfunction that occurs in these cortical-subcortical circuits, rather than
focusing on disruptions in functioning of the prefrontal cortex or subcortical systems
alone”.
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2.6 Conclusions
Despite the prevailing notion that schizophrenia is associated with severe
neurochemical and synaptic disturbances in several brain areas and circuitries based on
post-mortem findings, recent in vivo neuroimaging studies provide a contradictory view
in which the neurotransmitter abnormalities in the brains of patients living with
schizophrenia appear to be quite subtle. Consequently, it may be more difficult than
anticipated to draw sufficient parallels between these neuroimaging studies and the
previous preclinical models of behavioural flexibility which induced significant
pharmacological disruption of a given neurotransmitter/receptor system. In considering
the potential for subtle disturbances in multiple neurotransmitter systems in
schizophrenia, we investigated the consequence of combining acute systemic injections
of D1 receptor and NMDA receptor antagonists on behavioural flexibility in normal adult
rats as assessed with an operant conditioning based set-shifting task. Our results show
that behaviourally sub-effective doses of D1 and NMDA receptor antagonists cooperate
synergistically to cause disruption of set-shifting which is characterized by an increase
the occurrence of perseverative errors.
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Glutamate and dopamine abnormalities in the medial
prefrontal cortex act synergistically to cause executive
dysfunction
3.1 Abstract
Impairment of executive function is a core feature of schizophrenia, with patients
showing perseverance in tasks requiring behavioural flexibility. Abnormalities in
dopaminergic and glutamatergic neurotransmission within the prefrontal cortex have
been implicated in schizophrenia, and preclinical models have confirmed the importance
of these neurotransmitter systems in behavioural flexibility. The present study
investigated whether intra-medial prefrontal cortex (mPFC) co-infusion of dopamine D1
and glutamate N-Methyl-D-aspartic acid (NMDA) receptor antagonists at sub-effective
doses affect behavioural flexibility. Male Sprague-Dawley rats received bilateral intramPFC infusion of the dopamine D1 antagonist, SCH 23390, and the NMDA
uncompetitive antagonist, MK-801, at various doses, either alone or in combination prior
to performance of a lever-pressing set-shifting task. Task performance was sensitive to
the doses infused into the mPFC; the higher doses of antagonists (0.05 μg/side SCH
23390; 0.25 μg/side MK-801) each impaired set-shifting, whereas the separate infusion of
the lower doses (0.025 μg/side SCH 23390; 0.125 μg/side MK-801) was ineffective. As
predicted, the co-infusion of these lower doses significantly increased the number of
trials needed to complete the task and the number of perseverative errors committed,
while not affecting learning or memory retrieval. The synergistic effect of SCH 23390
and MK-801 on set-shifting performance confirmed that behavioural flexibility depends
on coincident activation of mPFC dopamine D1 and glutamate NMDA receptors. The
collective results support the suggestion that perseverance can manifest from a subtle
disruption in both dopaminergic and glutamatergic neurotransmission within the mPFC;
findings which are relevant for studies attempting to model schizophrenia
pathophysiology.
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3.2 Introduction
Executive function, comprising cognitive processes such as working memory,
attention and behavioural flexibility, enables us to solve problems, form strategies, and
adapt to unexpected conditions to achieve goals (Orellana and Slachevsky, 2013;
Rowland et al., 2013). Deficits in executive function are associated with a range of
disorders, including Alzheimer’s disease, attention deficit hyperactivity disorder
(ADHD), and schizophrenia (Elliott, 2003). For example, patients with schizophrenia
show difficulties in inhibiting a previously-learned strategy (i.e., they make perseverative
errors) during performance of the Wisconsin card sorting test (WCST)-a
neuropsychological assessment requiring behavioural flexibility (Bornstein et al., 1990;
Braff et al., 1991; Rosse et al., 1991; Abbruzzese et al., 1996; Perry and Braff, 1998;
Gooding et al., 1999; Everett et al., 2001; Prentice et al., 2008; Waford and Lewine,
2010; Orellana and Slachevsky, 2013). Based on the findings from functional
neuroimaging studies in healthy subjects as well as patients with schizophrenia, it is well
established that the dorsolateral prefrontal cortex (dlPFC) contributes to the successful
performance of the WCST (Weinberger et al., 1986; Andreasen et al., 1990; Berman et
al., 1995; Nagahama et al., 1996; Fletcher et al., 1998; Callicott et al., 2000; Monchi et
al., 2001; Passingham and Wise, 2014; Boschin et al., 2017). Similarly, preclinical
studies in rodents have identified the role of the medial prefrontal cortex (mPFC) in
executive function, as lesioning/inactivating this brain region causes impairments in
working memory (Ragozzino et al., 2002b; Yoon et al., 2008; O’Neill et al., 2013; Liu et
al., 2014), decision making (Sul et al., 2010; Euston et al., 2012; Lee and Seo, 2016) and
set-shifting (i.e., the shifting of attention from one stimulus dimension to another)
(Ragozzino et al., 1999, 2002a; Birrell and Brown, 2000; Block et al., 2007; Ragozzino,
2007; Floresco et al., 2008). Consistent with the deficits in set-shifting observed in
patients with schizophrenia, altered activity in the mPFC has been shown to cause
increased perseverance in rodent models (Birrell and Brown, 2000; Ragozzino, 2002a;
Stefani and Moghaddam, 2005; Block et al., 2007; Floresco et al., 2008; Enomoto et al.,
2011).
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Preclinical models have also confirmed the importance of dopaminergic and
glutamatergic neurotransmission within the mPFC in behavioural flexibility, as intramPFC infusion of individual D1 and NMDA receptor antagonists can impair
performance during set-shifting (Ragozzino et al., 2002a; Stefani et al., 2003; Stefani and
Moghaddam, 2005; Gauthier et al., 2014). In addition, we recently reported an increased
perseverance in rats following the systemic co-administration of dopamine D1 and
NMDA receptor antagonists at doses that were low enough to be ineffective at altering
set-shifting when injected separately (Desai et al., 2017). Because these “behaviourally
sub-effective” doses were injected systemically, it was not possible to conclude whether
this synergistic effect of antagonists on behavioural flexibility was mediated directly
through coincident deactivation of dopamine D1 and NMDA receptors within the mPFC.
That said, it is reasonable to predict that set-shifting could be impaired due to local mPFC
disruption of both the dopaminergic and glutamatergic neurotransmitter systems because
dopamine D1 and NMDA receptors are co-localized on pyramidal neurons and
interneurons within the PFC, and activation of these D1 receptors potentiates NMDAmediated calcium responses (Kruse et al., 2009). In further support of our working
hypothesis, a previous study on rats found that repetitive co-infusion of low, individuallyineffective doses of dopamine D1 and NMDA receptor antagonists into the mPFC
disrupted instrumental learning over a multi-day lever-pressing task (Baldwin et al.,
2002).
To determine if behavioural inflexibility requires coincident blockade of
dopamine D1 and NMDA receptors within the mPFC, we exposed rats to bilateral intramPFC infusion of the dopamine D1 antagonist, SCH 23390, and the NMDA
uncompetitive antagonist, MK-801, at various doses, either alone or in combination prior
to performance of a set-shifting task. Here, we report for the first time that the combined
infusion of these antagonists at doses that failed to impair performance when injected
alone ultimately resulted in increased perseverance; findings which support the
suggestion that a mild disruption in both dopaminergic and glutamatergic
neurotransmission within the mPFC is sufficient to cause significant impairment in
behavioural flexibility.
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3.3 Materials and methods
Animals
Fifty-six adult male Sprague-Dawley adult rats were used in this study (Charles
River, Quebec, Canada). All rats were kept in a facility with temperature- and humiditycontrolled rooms (24±2 °C, relative humidity 55±10%), where they were maintained on a
12-h light/dark cycle (lights on at 7:00 am). In preparation for behavioural training, rats
were food restricted up to 85-87% of their free feeding body weight, and they were
handled for approximately five minutes per day to get familiarized to the investigator.
During the last couple of days of food restriction, rats were given five sucrose pellets (45
mg; BioServ, Frenchtown, NJ, USA) in their home cage so that they could become
familiar with the pellets used as a positive reinforcement in the behavioural tasks.

Drugs
The glutamate NMDA receptor uncompetitive antagonist (+) MK-801
(dizocilpine hydrogen maleate) and dopamine D1 antagonist (R)-(+) SCH 23390
hydrochloride were obtained from Sigma-Aldrich (St. Louis, MO, USA), and dissolved
in sterile saline to achieve the following concentrations: MK-801 (0.125 and 0.25 g/0.5
L) and SCH 23390 (0.025 and 0.05 g/0.5 L). The doses of both antagonists were
based upon their salt form. Fresh solutions were prepared on the day of infusion, and
stored in a refrigerator. All infusions were made with solutions at room temperature.

Surgery
Rats were anesthetized with isoflurane (Forene®, Baxter Corporation,
Mississauga, ON, Canada), mounted in a stereotaxic frame, and injected with metacam
(Boehringer Ingelheim, Burlington, ON, Canada) and an antibiotic (Baytril®, Bayer Inc.,
Toronto, ON, Canada). For intra-mPFC drug infusion, bilateral guide cannulae (27 G, 2
mm length; RWD Life Science Inc., San Diego, CA, USA) were implanted using
stereotaxic coordinates to target the prelimbic cortex (relative to bregma: AP= + 3.24,
ML= ± 0.8, DV= −1.5 mm from skull surface; Paxinos and Watson, 2007). These guide
cannulae were secured to the skull with four screws and dental cement. Stainless steel
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dummy cannulae were inserted in the guide cannulae to prevent clogging prior to the
micro-infusion, which occurred several days later. Rats were allowed at least six days of
recovery from surgery before initiation of the food restriction. Over this period, rats were
handled daily during various procedures, including general holding, weighing and
cleaning of dummy cannulae.

Micro-infusion procedure
Intra-mPFC injections were performed in awake animals using infusion cannulae
that extended 2 mm beyond the length of the guide cannulae. On the experimental day,
rats received bilateral infusion of either the dopamine D1 receptor antagonist SCH 23390
(0.025 μg or 0.05 μg /0.5 μL/side), the uncompetitive NMDA receptor antagonist MK801 (0.125 μg or 0.25 μg /0.5 μL/side) or 0.9% sterile saline as vehicle (0.5 μL/side) into
the prelimbic region of the mPFC 7 min before the beginning of the set-shifting session
(Experiment 1) or the visual-cue learning paradigm (Experiment 2 Figure 3.1). In animals
that received the combination of SCH 23390 and MK-801, appropriate doses of these
antagonists were infused in a volume of 0.5 μL on each side. Both sides were infused
simultaneously using a microinfusion pump and Hamilton syringes connected to the
infusion cannula via Teflon tubing. Infusion were made over 5 min (0.1 μL/min), and the
infusion cannulae were then left in place for an additional 2 min to allow adequate
diffusion of the drug into the surrounding brain tissue.

Behavioural apparatus
Behavioural training and testing were performed in an operant conditioning
apparatus, which included a modular acrylic test chamber (30.5 x 24 x 21 cm), housed in
a sound-attenuating box. On the front wall of the test chamber were two stimulus lights,
each located above a retractable lever that was positioned on either side of a central pellet
receptacle. A house light was located on the back wall of the chamber. The chamber was
controlled by a customized computer software program (MED-PC IV, Med-Associates).
For example, when the rat pressed the lever that was considered a correct response, a
dispenser was triggered to release a sucrose pellet into the central pellet receptacle.
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Set-shifting task
Set-shifting was conducted as described in the previous chapter (see 2.3.4). One
day after performing the visual-cue discrimination task, rats received an intra-mPFC
bilateral infusion of one of the drug treatments (0.025 μg or 0.05 μg SCH 23390; 0.125
μg or 0.25 μg MK-801; 0.025 μg SCH 23390 + 0.125 μg MK-801; or 0.9% saline). Seven
minutes later, rats were subjected to 20 visual-cue discrimination trials to determine the
effect of the various drug treatments on memory retrieval of the initial strategy (i.e.,
follow the cue light). On the 21st trial, the paradigm was switched to a response
discrimination, in which the rats had to set-shift and now respond on the lever opposite to
their side bias during every trial regardless of the location of the stimulus light. Again,
each trial began with the random illumination of a stimulus light, followed 3 s later by the
extension of both levers. Correct lever presses within the 10 s response window resulted
in delivery of a sucrose pellet. The response discrimination session ended when either the
rat made 10 consecutive correct responses or if the maximum number of 120 trials was
performed. Total number of trials to criterion and errors committed to achieve criterion
were recorded.
In accordance with previous studies (Floresco et al., 2008; Desai et al., 2017), the
errors committed during the response discrimination task (i.e., set-shifting) were subdivided into three categories as perseverative, regressive or never-reinforced errors. An
error was considered “perseverative” or “regressive” if during the response
discrimination task, the rat pressed the lever associated with the illuminated stimulus
light when the opposite lever was correct. In a block of 16 randomized trials, 8 trials
required the rat to press the lever opposite to the stimulus light (i.e., the rat was faced
with a chance to make a perseverative error). If the rat committed 6 or more such errors
out of the 8 chances, these errors in that block were considered “perseverative” errors,
whereas 5 or fewer such errors were instead considered “regressive” errors, as the rat was
following the initial visual-cue strategy in less than 75% of trials (Floresco et al., 2008).
A “never-reinforced error” occurred when the stimulus light was illuminated above the
correct lever, yet the rat pressed the opposite lever; a choice that had never resulted in a
pellet in either the visual-cue or response discrimination task.
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3.3.6.1 Visual-cue learning paradigm
To determine if the intra-mPFC co-infusion of the lower doses of SCH 23390 +
MK-801 affected learning of a given lever-pressing rule as opposed to actual set-shifting,
we conducted an experimental on a separate group of naïve rats (Figure 3.7). Rats were
acclimatized and trained to press the levers using the same protocol as described before
(2.3.4). The next day, these rats received an intra-mPFC infusion of either 0.025 μg SCH
23390 + 0.125 μg MK-801 on each side (n=7) or vehicle (saline; n=7), and 7 min later,
were tested on their ability to learn the visual-cue discrimination task. These groups of
rats were never subjected to the set-shifting experiment.

Histology
Upon completion of the response discrimination task, rats were given an overdose
of sodium pentobarbital (Euthanol, 105 mg/kg, IP; MTC Pharmaceuticals, Cambridge,
ON, Canada), and then perfused trans-cardially with 0.9% saline followed by a solution
containing 4% formaldehyde in phosphate buffer (pH 7.4). Brains were extracted, postfixed in 4% formaldehyde solution overnight, and then cryoprotected by storing in 30%
sucrose at 4 °C for 3 days. Using a microtome, 40 μm coronal sections of mPFC were cut
and collected in phosphate buffer (pH 7.4). Sections were mounted on glass slides and
Nissl stained to verify cannulae placements (Figure 3.9). Every rat infused showed
cannula placement within the prelimbic area bilaterally, and consequently, all are
included in the analysis.

Statistical analysis
The effects of intra-mPFC drug infusion on visual-cue retrieval, trials and errors
to criterion, and number of omissions were analyzed by separate one-way analyses of
variance (ANOVA). Two-way mixed ANOVAs were used to determine the effect of
treatments on the type of errors committed, as well as the latency to respond on the
levers. In a separate group of rats, a two-tailed student’s t-test was used to compare the
performance of the visual-cue learning paradigm following infusion of the combined
drug treatment (0.025 μg SCH 23390 + 0.125 μg MK-801) versus the saline control. All
statistical analyses were conducted with α = 0.05 using GraphPad Prism 7.0 software.
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When needed, Tukey’s post hoc test was employed to compare the performance measures
across the various drug treatment groups. All data are presented as mean ± standard error
of mean (SEM).

Figure 3.1 Timeline of Experiment 1 and 2.
A) In Experiment 1, following handling and acclimatization to the chamber, the rats were
subjected to training. Once the rats achieved the criterion for the training session, their side
bias was determined on the final day of training. On the next day, rats were subjected to
visual-cue discrimination, and the following day was the response discrimination (setshifting) test. On the response discrimination day, the rats received bilateral intra-mPFC
infusion of drugs or vehicle, and 7 min later, they were subjected to 20 visual-cue
discrimination trials to determine the effect of drug treatments on retrieval of the memory
and motor function. On the 21st trial, the paradigm was switched from a visual-cue
discrimination to a response discrimination that lasted until either the rat made 10
consecutive correct responses or to the maximum number of 120 trials. B) Experiment 2
was performed on a separate group of naïve rats that received the bilateral intra-mPFC
infusion of drugs or vehicle prior to the initial exposure to the visual-cue discrimination
task. Rats employed in Experiment 2 were never subjected to set-shifting trials.
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3.4 Results
Effect of SCH 23390, MK-801 or combined antagonist infusion on
visual-cue retrieval
On the day set-shifting task was performed, the initial 20 trials after the intramPFC infusion required each rat to respond on the lever associated with the stimulus
light, thereby allowing for the investigation of the effect of the various drug infusion on
memory retrieval of the initial visual-cue discrimination strategy. As predicted based on
previous studies (Ragozzino et al., 2002a; c; Stefani et al., 2003; Stefani and
Moghaddam, 2005; Gauthier et al., 2014), none of the drug infusion affected memory
retrieval (one-way ANOVA, P>0.05; Figure 3.2), as all rats (n=7 per group) showed a
high level of performance.

Figure 3.2 Effect of intra-mPFC infusion of SCH 23390 and MK-801 alone or in
combination on visual-cue retrieval.
On the set-shift day (during the 20 trials prior to the response discrimination task), intra-

mPFC infusion of SCH 23390 and MK-801 alone or in combination did not affect retrieval
of the memory from the previous day (visual-cue discrimination task), as the number of
errors committed during the 20 visual-cue trials was comparable across groups (one-way
ANOVA, P>0.05). n=7 per group.

91

Effect of SCH 23390, MK-801 or combined antagonist infusion on
set-shifting
3.4.2.1 Number of trials to criterion
One-way ANOVA found that the various drug doses infused into the mPFC
differentially affected the number of trials needed to complete the set-shifting task
[F(5,36) = 11.8, P<0.0001; Figure 3.3]. Tukey’s post hoc testing further revealed that,
compared to vehicle-treated controls (n=7), the groups of rats infused with the higher
dose of either SCH 23390 (0.05 g/side; n=7) or MK-801 (0.25 g/side; n=7) showed a
significant increase in the total number of trials to criterion (Figure 3.3). In contrast, the
lower doses of SCH 23390 (0.025 g/side) or MK-801 (0.125 g/side) were ineffective
at altering set-shifting performance.
As predicted, Tukey’s post hoc testing confirmed that the groups of rats that
received the co-infusion of the lower, “behaviourally sub-effective” doses of SCH 23390
(0.025 g/side) and MK-801 (0.125 g/side) showed an increased number of trials to
complete the set-shifting task compared to controls (P<0.0001) as well as the individual,
lower dose groups (0.025 g/side SCH 23390 alone, P<0.01; 0.125 g/side MK-801
alone, P<0.001).
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Figure 3.3 Effect of intra-mPFC infusion of SCH 23390 and MK-801 alone or in
combination on trials to criterion during set-shifting.
Intra-mPFC infusion of the individual lower doses of SCH 23390 (0.025 g/side) or MK801 (0.125 g/side) did not affect number of trials to criterion (P>0.05) as compared to
control group. In contrast, the higher dose of SCH 23390 (0.05 g/side) significantly
increased the number of trials to criterion as compared to the control (***P<0.001),
lower dose SCH 23390 ($$P<0.01) and lower dose MK-801 groups (###P<0.001).
Similarly, infusion of the higher dose of MK-801 (0.25 g/side) significantly increased
the trials to criterion as compared to the control (*P<0.05) and lower dose MK-801
groups (#P<0.05). As predicted, the co-infusion of the lower doses of SCH 23390 and
MK-801 significantly increased the trials to criterion as compared to the control
(****P<0.0001), lower dose SCH 23390 ($$P<0.01) or lower dose MK-801 groups
(###P<0.001). Finally, the number of trials to criterion following the individual higher
dose infusion was comparable to the co-infusion group (P>0.05). One-way ANOVA

followed by Tukey’s post hoc tests. n=7 per group.
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3.4.2.2 Number of errors to criterion
One-way ANOVA revealed effects of different drug treatments on number of
errors committed during set-shifting task [F(5,36) = 14.82, P<0.0001; Figure 3.4]. Post
hoc analysis revealed that, compared to control group (n=7), the groups infused with the
higher dose of either SCH 23390 (0.05 g/side; n=7) or MK-801 (0.25 g/side; n=7)
showed a significant increase in errors to criterion.
Co-infusion of lower doses of SCH 23390 and MK-801 significantly increased
number of errors committed as compared to the controls (P<0.001) or separate lower
dose infusion of SCH 23390 (P<0.001) or MK-801 (P<0.0001).
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Figure 3.4 Effect of intra-mPFC infusion of SCH 23390 and MK-801 alone or in
combination on errors to criterion during set-shifting.
The number of errors committed by either of the groups receiving the lower doses of SCH
23390 (0.025 g/side) or MK-801 (0.125 g/side) were comparable to those committed
by the control group (P>0.05). Following infusion of the higher dose of SCH 23390 (0.05
g/side), rats committed significantly more errors as compared to the control
(****P<0.0001), lower dose SCH 23390 ($$$P<0.001) and lower dose MK-801 groups
(####P<0.0001). In agreement, intra-mPFC infusion of the higher dose of MK-801 (0.25
g/side) significantly increased the number of errors committed versus the control
(*P<0.05), lower dose SCH 23390 ($P<0.05) and lower dose MK-801 groups
(##P<0.01). Co-infusion of the lower, individually-ineffective doses of SCH 23390 and
MK-801 significantly increased the number of errors made compared to the control
(***P<0.001), lower dose SCH 23390 ($$$P<0.001) and lower dose MK-801 groups
(####P<0.0001). Lastly, the number of errors committed by either of the higher dose

groups was comparable to those of the co-infusion group. One-way ANOVA followed by
Tukey’s post hoc tests. n=7 per group.
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3.4.2.3 Type of errors
Errors committed during the set-shifting task were divided in three subgroups
(perseverative, regressive and never-reinforced errors) and the effect of the different drug
infusion on these error types was analyzed using a two-way, mixed ANOVA with
“treatment” as the between-subject factor and “error type” as the within-subject factor, as
described previously (Darrah et al., 2008; Floresco et al., 2008; Snyder et al., 2015; Desai
et al., 2017). In addition to reporting significant main effects for both treatment [F(5,30)
= 15.94, P<0.0001] as well as error type [F(2,12) = 967.7, P<0.0001], the two-way,
mixed ANOVA found an interaction between the factors [F(10,60) = 11.19, P<0.0001].
Ultimately, Tukey’s post hoc testing revealed a significant increase in perseverative
errors committed by the co-infusion group (0.025 μg/side SCH 23390 + 0.125 μg/side
MK-801) compared to the saline (P<0.0001), lower dose SCH 23390 (P<0.0001) or
lower dose MK-801 groups (P<0.0001) (Figure 3.5). The number of regressive and
never-reinforced errors did not differ between groups (P>0.05).

Figure 3.5 Intra-mPFC infusion of SCH 23390 and MK-801 alone or in combination
differentially affected the error profile during set-shifting.
Both groups that received the individual higher doses of the antagonists (SCH 23390 0.05

g/side; MK-801 0.25 g/side) showed a significant increase in the number of perseverative
errors made compared to the control (****P<0.0001), lower dose SCH 23390 (0.025 g)
($$$$P<0.0001) and lower dose MK-801 groups (0.125 g) (####P<0.0001). Similar results were
observed for the group co-infused with the lower doses of the SCH 23390 + MK-801. The
number of regressive and never-reinforced errors was not changed across groups (P>0.05).
Mixed two-way ANOVA followed by Tukey’s post hoc tests. n=7 per group.
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Response latencies and omissions
For rats in each of the drug infusion groups, the latency to respond on the
extended levers was compared for last five trials of the following trial types: i) correct
response on non-perseverative trials, ii) correct response on trials where a perseverative
error was possible, and iii) perseverative error trials. Response latencies did not differ
between groups or during the various trial types (two-way mixed ANOVA, P>0.05;
Figure 3.6). These data suggest that motor function was not affected by the various drug
infusion.

Figure 3.6 Effect of intra-mPFC infusion of antagonists alone or in combination on latencies
to response during different types of trial.
Latencies to respond on the extended lever during the different types of trials were not affected by
the treatment groups (two-way ANOVA, P>0.05). Different types of trial included: i)
Correct/non-perseverative: A trial where the rat chose the correct lever when the illuminated
visual-cue light was associated with the correct lever; ii) Correct perseverative chance: A correct
response on a trial where a perseverative error was possible; and iii) Perseverative error: An

incorrect choice where the rat responded on the lever with the visual-cue light illuminated above
it when the opposite lever was correct. n=7 per group.
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Omissions
The number of omissions made during the set-shifting task was comparable
across all the groups (one-way ANOVA, P>0.05; Figure 3.7).

Figure 3.7 Effect of intra-mPFC infusion of antagonists alone or in combination on the
number of omissions committed during set-shifting.
None of the treatments significantly changed the number of omissions committed during
set-shifting as compared to the vehicle group (One-way ANOVA, P>0.05, n=7 per group).
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Effect of co-infusion of receptor antagonists on visual-cue learning
In Experiment 2, the separate group of naïve rats (n=7) that received the bilateral
intra-mPFC saline infusion prior to the visual-cue learning paradigm were able to
complete the task in ~30 trials (Figure 3.8). Compared to these controls, the rats (n=7)
that received the co-infusion of the lower doses of SCH 23390 + MK-801 (0.025 μg/side
SCH 23390 + 0.125 μg/side MK-801) did not differ in the number of trials to criterion
[two-tailed student’s t-test, t(12)=0.775, P>0.05]. Thus, the intra-mPFC co-infusion of
these “behaviourally sub-effective” doses of antagonists did not affect the rats’ ability to
learn a new set of rules.

Figure 3.8 Intra-mPFC co-infusion of the lower, individually-ineffective doses of
antagonists did not impair learning.
In Experiment 2, in a separate group of rats (n=7), prior to performance of the initial
visual-cue discrimination task, the lower doses of SCH 23390 (0.025 g/side) and MK801 (0.125 g/side) were co-infused into the mPFC. This combined treatment did not
affect visual-cue learning as compared to the control group (n=7) that received saline

infusion prior to performing the task (student’s t-test, P>0.05).
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B

Figure 3.9 Representative histology and reconstruction of infusion cannulae location in
mPFC.
A) A photomicrograph showing that the bilateral infusion cannulae targeted the prelimbic (PL)

region of the mPFC in a representative animal. B) Schematic images of successive coronal
sections (adapted from Paxinos and Watson 2007) showing the location of the ends of the
infusion cannulae in all animals used in the present study (n=56).

100

3.5 Discussion
In the present study, we used an operant conditioning-based task in rats to
investigate if the combined, intra-mPFC infusion of low, individually-ineffective doses of
dopamine D1 and NMDA receptor antagonists would be sufficient to impair set-shifting.
Ultimately, in agreement with our working hypothesis, we report for the first time that
coincident blockade of dopamine D1 and NMDA receptors in the mPFC is impairs
behavioural flexibility. Moreover, our collective findings support the suggestion that
perseverance can manifest from a seemingly mild but coincidental disruption in both
dopaminergic and glutamatergic neurotransmission within the mPFC.
Over the past two decades, a variety of preclinical rodent models have been
developed to investigate the brain regions and neurotransmitter systems underlying
deficits in set-shifting, with many of these models being based on digging behaviour,
maze navigation or conditioned lever-pressing in operant chambers (Birrell and Brown,
2000; Stefani et al., 2003; Ghods-Sharifi et al., 2008; Enomoto et al., 2011; Tait et al.,
2014). Largely consistent among these set-shifting tasks, rodents must suppress their
actions associated with a previously-learned response, rule or strategy, successfully
sample novel strategies and eliminate those that are disadvantageous, and finally, adhere
to the newly-effective strategy (Block et al., 2007; Floresco et al., 2008, 2009).
Importantly, these overlapping stages of set-shifting appear to have a differential
susceptibility to disturbed activity in certain brain regions, as evidenced with distinct
error profiles. For example, local damage/inactivation of the mPFC results in an inability
to disengage from the initial strategy (i.e., increased perseverative errors) (Ragozzino et
al., 1999; Ghods-Sharifi et al., 2008; Enomoto et al., 2011), whereas as the number of
never-reinforced or regressive errors were increased following inactivation of the nucleus
accumbens (Floresco et al., 2006a) or dorsal striatum (Ragozzino et al., 2002c),
respectively.
In addition to lesioning/inactivating the mPFC, it is well established that the
number of perseverative errors also increases following local blockade of the
dopaminergic (Crofts et al., 2001; Ragozzino, 2002a; Floresco et al., 2006b) or
glutamatergic neurotransmitter systems (Stefani et al., 2003; Stefani and Moghaddam,
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2005). In agreement with these previous studies, we found that intra-mPFC infusion of
the higher doses of either the dopamine D1 receptor antagonist, SCH 23390, or the
uncompetitive NMDA receptor antagonist, MK-801, caused impaired set-shifting via
increased perseverance. In considering the effect of the separate disturbance of
dopaminergic or glutamatergic neurotransmission within the mPFC, it is worth noting
that the individual doses used to impair set-shifting in the present study (SCH 23390:
0.05 g/side; MK-801: 0.25 g/side) were previously found to be ineffective at altering
performance during various working memory tasks (Seamans et al., 1998; Romanides et
al., 1999; Rios Valentim et al., 2009; Rodrigues et al., 2011; Auger and Floresco, 2017).
Taken together, these findings highlight the seemingly heightened susceptibility of
behavioural flexibility to altered neurotransmission within the mPFC.
To investigate our working hypothesis that intra-mPFC synergism between
dopamine and glutamate abnormalities cause impaired set-shifting, a group of rats were
infused intra-mPFC with a combination of the doses of SCH 23390 and MK-801 that
were low enough to be ineffective at impairing set-shifting when infused separately. As
predicted, the intra-mPFC co-infusion caused a significant increase in the number of
trials and errors to criterion as well as perseverative errors committed. To our knowledge,
these results provide the first evidence that behavioural flexibility is sensitive to a mild
degree of co-disruption of dopamine D1 and NMDA receptors within the mPFC. In fact,
set-shifting appears to be particularly sensitive to disruption in both dopaminergic and
glutamatergic neurotransmission as the doses of antagonists used to cause perseverance
failed to affect either the acquisition of the visual-cue strategy or memory retrieval.
However, in contrast to these null effects, Baldwin et al, (2002) reported that daily coinfusion of low, individually-ineffective doses of dopamine D1 and NMDA receptor
antagonists into the mPFC impaired the acquisition of a lever-pressing behaviour over a
multi-day instrumental learning task. It is reasonable to suggest that these disparate
results on learning could be due to the actual doses used (e.g., SCH 23390: 0.025 μg/side
in the present study vs. 0.05 μg/side in Baldwin et al, (2002) as well as differences in the
task demands (e.g., unlike in the present study, the first exposure their rats had to leverpressing occurred following co-infusion of the antagonists). Irrespective of the
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experimental differences between studies, the collective findings identify the importance
of coincident activation of dopamine D1 and NMDA receptors in the mPFC.
At present, it remains unknown, which cellular mechanisms underlie the impaired
set-shifting observed following co-infusion of the dopamine D1 and NMDA receptor
antagonists. That said, considerable research has investigated the interactions between D1
and NMDA receptors. There is evidence of co-localization of dopamine D1 receptors and
NMDA receptors in the same pyramidal neuron or interneuron in the PFC (Kruse et al.,
2009), and numerous in vitro studies have shown a synergism at the receptor level
between the D1 and NMDA receptors. For example, NMDA receptors were shown to
modulate D1 receptor-mediated functions, as blocking NMDA receptors leads to an
attenuation of the ability of the D1 receptor to affect neuronal activity (Huang et al.,
1998; Zheng et al., 1999). Reciprocally, activation of D1 receptors is known to
upregulate the activity of NMDA receptors (Gurden et al., 2000; Wang and O’Donnell,
2001; Chen and Yang, 2002; Flores-Hernández et al., 2002; Chen et al., 2004; Hallett et
al., 2006; Kruse et al., 2009; Sarantis et al., 2009; Varela et al., 2009; Li et al., 2010; Nai
et al., 2010). Moreover, uncoupling of the D1-NMDA interaction was found to prevent
the D1 receptor-induced upregulation of long-term potentiation (LTP) (Nai et al., 2010).
In addition to the aforementioned D1-NMDA interactions, it has been shown that
D1 receptors can modulate NMDA currents through a PKA-dependent intracellular
signaling pathway (Flores-Hernández et al., 2002; Cepeda and Levine, 2006). At the level
of animal behaviour, Kelley and colleagues reported that the repeated infusion of a
selective PKA inhibitor into either the mPFC (Baldwin et al., 2002) or nucleus
accumbens (Smith-Roe and Kelley, 2000) of rats attenuated instrumental learning during
a multi-day lever-pressing task; findings that were consistent to those following coinfusion of individually-ineffective doses of dopamine D1 and NMDA receptor
antagonists. Given that we found an impairment in set-shifting following similar coinfusion of receptor antagonists into the mPFC, it will be important for future studies to
determine if the selective inhibition of the PKA-pathway influences behavioural
flexibility.
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The increased perseverance observed in the present study following the intramPFC co-infusion of individually-ineffective doses of dopamine D1 and NMDA
antagonists is consistent with the error profile of schizophrenia patients performing the
WCST, as patients demonstrate difficulties in inhibiting a previously-learned strategy
(Braff et al., 1991; Rosse et al., 1991; Abbruzzese et al., 1996; Perry and Braff, 1998;
Gooding et al., 1999; Everett et al., 2001). Based on post-mortem studies of
schizophrenia brains, a considerable loss of γ-amino butyric acid (GABA)-ergic,
dopaminergic and glutamatergic activity in multiple cortical and subcortical areas has
been proposed (Akil et al., 1999; Clinton and Meador-Woodruff, 2004; Lewis et al.,
2005; Lewis, 2014; Hu et al., 2015; Poels et al., 2015; Weinstein et al., 2017). For
example, within the dlPFC of post-mortem schizophrenia brains, there is a 30% loss of
dopaminergic fibers, as well as a severe loss of dendritic spines (Glantz and Lewis,
2000), which suggests a corresponding loss of glutamatergic synapses. On the contrary, a
recent study using positron emission tomography (PET) described a significant but small
decrease in dopamine levels in the dlPFC in schizophrenia patients compared to controls,
and proposed that the loss of dopaminergic activity could be minimal (Slifstein et al.,
2015). Ultimately, the results of the present study along with those of Baldwin et al,
(2002) offer an important consideration for the future modeling of schizophrenia
pathophysiology, as minimal but simultaneous blockade of dopamine D1 and NMDA
receptors in the mPFC were found to be sufficient to significantly impair cognitive
function.
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Molecular mechanisms associated with D1-NMDA receptor
interaction mediated set-shifting in rats
4.1 Abstract
Prefrontal cortical interactions between dopamine and glutamate receptors are
known to control cognitive functions. In our previous study, synergistic interaction
between dopamine D1 and glutamate N-Methyl-D-aspartate (NMDA) receptor
antagonists in the medial prefrontal cortex (mPFC) caused impaired set-shifting in rats.
To find out molecular mechanisms underlying D1-NMDA receptor interaction in mPFC,
we investigated i) involvement of protein kinase A (PKA) pathway in D1-NMDA
receptor interaction mediated set-shifting behaviour ii) role of cortical extracellular
regulated kinase (ERK) transduction signaling in set-shifting and iii) role of D1-NMDA
receptor protein-protein interaction in set-shifting behaviour. We observed that, elevating
mPFC levels of PKA by rolipram ameliorated set-shifting deficits caused by intra-mPFC
co-infusion of behaviourally sub-effective doses of D1-NMDA receptor antagonists.
Inhibiting ERK phosphorylation by intra-mPFC infusion of mitogen-activated protein
kinase (MAPK) inhibitor PD98059 resulted in deficits in set-shifting behaviour.
PD98059-induced set-shifting impairments were not ameliorated by rolipram. Blocking
protein-protein interaction between D1 and NMDA by Fyn kinase inhibitor- PP2 did not
have any effect on set-shifting behaviour. In conclusion, in the mPFC, a strong
synergistic interaction between D1 and NMDA receptors exist, which regulates setshifting behaviour through PKA pathway. Further, for normal set-shifting, activation of
ERK cascade is essential in the mPFC; and ERK signaling is downstream to PKA
regulating set-shifting. Lastly, protein-protein interaction between D1-NMDA receptors
through Fyn kinase does not have any role in set-shifting behaviour.
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4.2 Introduction
Executive functions are higher-order cognitive processes comprising behavioural
flexibility (set-shifting and reversal learning), working memory and selective attention;
and they are necessary for normal daily life activities including planning, problemsolving, learning from the outcomes, changing responses and carrying out goal-directed
behaviours (Hughes and Graham, 2002). A number of psychiatric disorders including
schizophrenia, Alzheimer’s disease, autism and attention deficit hyperactivity disorder
(ADHD) show impaired executive functions (Bornstein et al., 1990; Braff et al., 1991;
Ozonoff, 1995; Collette et al., 1999; Perry and Hodges, 1999; Duke and Kaszniak, 2000;
Elliott, 2003; Hill, 2004; Orellana and Slachevsky, 2013; Reddy et al., 2016). Across
species studied, the prefrontal cortex (PFC) plays an important role in mediating
executive function (Ragozzino et al., 1999; Monchi et al., 2001; Floresco et al., 2008;
Moore et al., 2009; Tsuchida and Fellows, 2013; Déziel et al., 2015; Dalton et al., 2016).
Infusion of dopamine D1, glutamate N-Methyl-D-aspartate (NMDA) or gammaAminobutyric acid (GABA)-A receptor antagonists separately into the medial PFC
(mPFC) cause impairment in working memory, set-shifting as well as attention in rodents
(Seamans et al., 1998; Granon et al., 2000; Smith-Roe and Kelley, 2000; Ragozzino,
2002; Stefani et al., 2003; Moghaddam and Jackson, 2003; Stefani and Moghaddam,
2005; Paine and Carlezon, 2009; Enomoto et al., 2011; Su et al., 2014; Gauthier et al.,
2014; Paine et al., 2015; Auger and Floresco, 2017). We have recently reported impaired
set-shifting in normal adult rats following systemic or intra-mPFC administration of D1
receptor antagonist, SCH 23390, and a non-competitive NMDA receptor antagonist, MK801, in combination at doses that are ineffective when administered separately (Desai et
al., 2017; see results, 3.4.2). This suggest a synergistic role for D1 and NMDA receptors
in the mPFC in regulating set-shifting. Extensive literature has reported functional
interactions between D1 and NMDA receptors playing critical role in reward, attention,
locomotor activity, positive reinforcement, latent learning and working memory
(Pulvirenti et al., 1991; Smith-Roe and Kelley, 2000; Kreipike and Walker, 2004; Missale
et al., 2006; Castner and Williams, 2007; Mouri et al., 2007; Agnoli and Carli, 2011;
Bishop et al., 2011; Wang et al., 2012a, 2012b). It is possible that D1 and NMDA
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receptors from separate neurons of the mPFC to mediate such interaction via synaptic
connections. Nevertheless, D1 receptors and NMDA receptors have been found to be
present in same glutamatergic and GABAergic neurons of the mPFC and possibly
localized in close proximity to each other (Kruse et al., 2009), and therefore, an
intraneuronal D1-NMDA interaction cannot be overlooked.
Synergistic interactions between D1 and NMDA receptors in the PFC and the
nucleus accumbens in regulating cognitive processes such as working memory and
instrumental learning have been investigated previously (Smith-Roe and Kelley, 2000;
Baldwin et al., 2002b; Mouri et al., 2007; Rios Valentim et al., 2009). Baldwin et al.
(2002b) reported that combined infusion of sub-effective doses of NMDA and D1
receptor antagonists into the mPFC impaired instrumental learning in rats. In the same
study, authors found that inhibiting protein kinase A (PKA) in the mPFC replicated effect
of combined blocker treatment suggesting that cyclic AMP (cAMP)-dependent PKA
cascade is involved in D1-NMDA interaction associated with the instrumental learning.
Furthermore, in mice infusion of a D1 receptor agonist into the PFC attenuated the latent
learning impairment caused by phencyclidine (PCP; a NMDA receptor antagonist), as
well as decreased levels of learning associated phosphorylation of NR1 subunit of
NMDA receptors in the mPFC suggesting a functional link between dopaminergic D1
and glutamatergic NMDA receptor signaling through PKA (Mouri et al., 2007). In
addition, NMDA-mediated cytosolic Ca++ elevation was enhanced by a D1 receptor
agonist and this effect was blocked by PKA inhibitor (Kruse et al., 2009) (Figure 4.1).
Moreover, in hippocampal-PFC synapses, NMDA-induced long-term potentiation (LTP)
and excitability of pyramidal neurons were increased by D1 agonist or PKA activator
while D1 antagonist or PKA blocker attenuated this effect (Gurden et al., 2000; Wang
and O’Donnell, 2001). Although from aforementioned studies, it seems that PKA cascade
plays a facilitatory role in D1-NMDA interaction and regulates cognitive behaviours and
LTP, deleterious effect of PKA activation on working memory has also been reported
(Taylor et al., 1999).
In addition to PKA, signaling mediated by the extracellular signal-regulated
kinases (ERKs) also appears to play an important role in the synergistic interaction

117

between D1 and NMDA receptors. Co-infusion of small concentrations of D1 agonist and
NMDA receptor agonists increased the levels of phosphorylation of NMDA and AMPA
receptor subunits as well as ERK1/2, levels and this effect was blocked by inhibitors of
ERK phosphorylation (Sarantis et al., 2009) suggesting that ERKs are downstream
molecules involved in D1-NMDA interaction, and in turn ERK may facilitate excitatory
neurotransmission by phosphorylating NMDA and AMPA receptor subunits (Figure 4.1).
A separate mechanism underlying D1-NMDA receptor interaction has been proposed by
Nai et al. (2010) who reported NMDA-D1 direct protein-protein interaction, which
facilitated LTP and working memory in rats.
Evidence indicate that interactions between D1 and NMDA receptors also occur
through Fyn kinase pathway allowing functional cross-talk and potentiation of both types
of receptors independent of PKA mechanism (Lee et al., 2002; Scott et al., 2002, 2006;
Fiorentini et al., 2003; Cepeda and Levine, 2006; Li et al., 2010; Nai et al., 2010) (Figure
4.1). Fyn kinase, a Src kinase family member (non-receptor tyrosine kinases), is activated
following D1 receptors stimulation via ,  subunits of Gs protein and in turn
phosphorylates NR2B subunit of NMDA receptors at Tyr1472, rendering NMDA
receptors to be more effective in Ca++ conductance (Nakazawa et al., 2001). Moreover, a
recent study identified strong evidence for reduced Src-family kinase activity in the PFC
of post-mortem brains of patients with schizophrenia, a condition characterized by
impaired executive function, and it has been proposed that Src-family kinases in the PFC
might play a central role in cognitive deficits of schizophrenia (Hahn, 2011; Banerjee et
al., 2015).
Based on the above evidences, it appears that there is at least three main signaling
pathways potentially mediate intraneuronal interaction between D1 and NMDA receptors
in the mPFC. These are, i) PKA signaling; ii) ERK phosphorylation cascade and iii) Fyn
kinase-mediated augmentation of NMDA function (Figure 4.1). In current study, we
sought to investigate the role of PKA, ERK and Fyn kinase in regulating set-shifting.
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Figure 4.1 Prefrontal cortical D1-NMDA receptor interactions and molecular signalling
cascades associated with them.

Stimulation of D1 receptors trigger adenylyl cyclase (AC)/cAMP/PKA cascade (Wang et al.,
2002). Although DARPP-32 is present in PFC, it may not be playing a crucial role in D1
stimulation-activated protein kinase A (PKA) signalling cascade in the PFC (Sarantis et al.,
2009). NMDA receptor stimulation results in activation of signalling mechanism which
ultimately increase phosphorylation of extracellular regulated kinase 1/2 (ERK1/2) through
mitogen-activated protein kinase (MAPK) pathway (Chandler et al., 2001). D1-induced
increase in PKA levels were found to potentiate NMDA mediated excitability as well as Ca++
influx of cortical pyramidal neurons (Wang and O’Donnell, 2001; Gonzalez-Islas and Hablitz,

2003; Tseng and O’Donnell, 2004; Kruse et al., 2009). Further, coincidental activation of D1
and NMDA receptors or stimulation of D1 receptors found to cause increased
phosphorylation of NMDA receptor subunits through ERK1/2 pathway (Nagai et al., 2007;
Sarantis et al., 2009). Along with PKA and ERK pathways, D1-NMDA receptors interact with
each other by direct protein-protein interaction through Fyn kinase-dependent mechanism; and
a Fyn kinase inhibitor can disrupt this interaction (Gao and Wolf, 2008; Hu et al., 2010; Nai et
al., 2010).

119

4.3 Materials and methods
Animals
Adult male Sprague-Dawley rats were used in this study (Charles River, Quebec,
Canada). All rats were kept in facility with temperature- and humidity-controlled rooms
(24±2 °C, relative humidity 55±10%). A12 h light/dark cycle (lights on at 7:00 am) was
maintained. In preparation for behavioural training, rats were food restricted up to 8587% of their free feeding body weight, and they were handled for approximately five
minutes per day to get familiarized to the investigator. During the food restriction, rats
were given five sucrose pellets for the last five days prior to the start of training (45 mg;
BioServ, Frenchtown, NJ) to make them to be familiar with the pellets that are used as a
positive reinforcement in the behavioural tasks. All measures were taken to minimize the
pain and suffering to animals at all time. Animals showing set-shifting deficit following
drug treatments were reused one more time in this study. From our data, in naïve
untreated animals, a 5-day washout period following the first run of set-shifting did not
alter their performance on second run as the number of trials and errors to criterion as
well as different types of errors committed during the first and second set-shifting were
comparable (see results, 4.4.1). Our data is in accordance with Wallace et al. (2014).
After washout period (5 days), animals to be reused were taken through exact same steps
as their first exposure of set-shifting (n=14). All procedures were approved by the
Institutional Animal Care Committee and are following the Canadian and National
Institute of Health Guides for the Care and Use of Laboratory Animals (NIH Publication
#80-23).

Drugs
The glutamate NMDA receptor uncompetitive antagonist (+) MK-801 (5S,10R)(+)-5-methyl-10,11-dihydro-5H-dibenzocyclohepten-5,10-imine hydrogen maleate;
dizocilpine hydrogen maleate) and selective dopamine D1 receptor antagonist (R)-(+)
SCH 23390 hydrochloride (R(+) 7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5tetrahydro-1H-3-benzazepine hydrochloride) were dissolved in sterile saline to get
desired concentrations. Fyn kinase inhibitor, PP2 (4-amino-3-(4-chlorophenyl)-1-(tbutyl)-1H-pyrazolo[3,4-d]pyrimidine; a selective inhibitor of Src family kinases with
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very high affinity to Fyn kinase), mitogen-activated protein kinase (MAPK) inhibitor,
PD98059 (2ʹ-Amino-3ʹ-methoxyflavone; a selective inhibitor of MAP kinase kinase –
MEK), and a selective inhibitor of phosphodiesterase 4 (PDE4), rolipram (4-[3(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) were dissolved in 3 %
dimethylsulfoxide (DMSO) to achieve desired concentrations. All the drugs were
procured from Sigma-Aldrich (St. Louis, MO, USA). Fresh solutions were prepared on
the day of injection, and stored in a refrigerator between injections in successive animals.
All infusions were made with solutions at room temperature. Control group of animals
received infusion of sterile saline or 3% DMSO in saline as appropriate.

Surgery
Rats were anesthetized with isoflurane (Forene®, Baxter Corporation,
Mississauga, ON Canada), mounted in a stereotaxic frame, and injected with Metacam
(Boehringer Ingelheim, Burlington, ON, Canada) and an antibiotic (Baytril®, Bayer Inc.,
Toronto, ON, Canada). For intra-mPFC drug infusion, bilateral guide cannulae (27 G, 2
mm length; RWD Life Science Inc., San Diego, CA, USA) were implanted using
stereotaxic coordinates to target the prelimbic cortex (relative to bregma: AP= + 3.24,
ML= ± 0.8, DV= −1.5 mm from skull surface; Paxinos and Watson, 2007). These guide
cannulae were secured to the skull with four jeweller’s screws and dental cement.
Stainless steel dummy cannulae were inserted into the guide cannulae to prevent clogging
in between the micro-infusion. During surgical recovery period, rats were handled daily
at various procedures, including general care, weighing and cleaning of dummy cannulae.

Micro-infusion procedure
Intra-mPFC injections were performed in awake animals using infusion cannulae
that extended 2 mm beyond the length of the guide cannulae. On the experimental day,
rats received one of the following bilateral infusion into the mPFC: i) co-infusion of
rolipram (2.5 μg) with SCH 23390 (0.025 μg) + MK-801 (0.125 μg); ii) rolipram alone
(2.5 μg); iii) PD98059 alone (2.67 μg); iv) co-infusion of rolipram (2.5 μg) + PD98059
(2.67 μg); v) PP2 alone (3.0 ng); vi) vehicle (3% DMSO or saline). For co-infusion,
drugs solutions were diluted to obtain the appropriate concentrations of individual drugs
in 0.5 μL volume per site. Doses of PD98059 and PP2 we chose were commonly used in
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in vivo studies where they showed impaired cognitive functions and expected changes in
the levels phosphoproteins (Grosshans and Browning, 2001; Bevilaqua et al., 2003;
Gerdjikov et al., 2004; Nagai et al., 2007; Liu et al., 2014). In addition, in pilot studies,
we have verified efficacy and possible motor effects of rolipram, PD98059 and PP2 that
could interfere non-specifically with behavioural testing (2-3 doses per drug; 2-3 rats per
group). Both sides were infused simultaneously using a microinfusion pump and
Hamilton syringes connected to the infusion cannula via Teflon tubing. Infusions were
made over 5 min (0.1 μL/min), and the infusion cannulae were left in place for an
additional 2 min to allow diffusion of the drug into the surrounding brain tissue and to
minimize solutions escaping via the cannula tract.

Behavioural apparatus
Behavioural training and testing was performed in an operant conditioning
apparatus, which included a modular acrylic test chamber (30.5 x 24 x 21 cm). Front wall
of the test chamber had two stimulus lights, each located above a retractable lever that
was positioned on either side of a central pellet receptacle. A house light was located on
the back wall of the chamber. The chamber was operated through a customized computer
software program (MED-PC IV, Med-Associates). Trial by trial data was recorded during
all the procedures performed in the box.

Set-shifting task
Behavioural flexibility was assessed using a set-shifting task adapted from
Floresco et al. (2008). This task has been described in detail in our recent study (Desai et
al., 2017 see 2.3.4). Following series of steps were involved in testing set-shifting:
acclimatization and training, side-bias determination, initial set formation (visual-cue
discrimination) and set-shifting (response discrimination).

Histology
Following set-shifting, rats were given an overdose of sodium pentobarbital
(Euthanol, 105 mg/kg, i.p.; MTC Pharmaceuticals, Cambridge, ON, Canada), and
intracardially perfused with 0.9% saline followed by a solution containing freshly
prepared 4% formaldehyde in phosphate buffer (pH 7.4). Brains were extracted, post-
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fixed in the same formaldehyde solution overnight, and then cryoprotected by storing in
30% sucrose in phosphate buffer at 4 °C for 3-4 days. Using a microtome, 40 μm coronal
sections through the mPFC were cut and collected in phosphate buffer. Sections were
mounted on glass slides and Nissl stained to verify cannulae placements (Figure 4.12).

Statistical analysis
Effect of co-infusion of rolipram with dual combination on visual-cue retrieval,
trials and errors to criterion, and number of omissions committed during set-shifting was
analyzed by one-way analysis of variance (ANOVA). A two-way mixed ANOVA was
used to determine the effect of treatments on the type of errors committed, as well as the
latency to respond on the levers. Following ANOVAs, if needed, Tukey’s or Bonferroni’s
post hoc test was employed to compare the performance measures across the groups. A
two-tailed student’s test was used to assess effect of re-exposure of set-shifting, effect of
PD98059 and PP2 on visual-cue retrieval, trials and errors to criterion during set-shifting
and number of omissions committed during set-shifting in comparison with respective
control groups. Further, student’s t-test was also used to assess effect of PD98059 on
visual-cue learning. All statistical analyses were conducted with  = 0.05 using
GraphPad Prism 7.0 software. All data are presented as mean  standard error of mean
(SEM).
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4.4 Results
Effect of re-testing rats on behavioural pattern during set-shifting.
4.4.1.1 Trials and errors to criterion
Following first set-shifting rats were given washout period of 5 days. Re-exposure
to training and set-shifting did not affect number of trials [t(10)=0.4593, P>0.05] (n=6)
and errors to criterion [t(10)=0.3339, P>0.05] (n=6; Figure 4.2 A,B; student’s t-test).

Figure 4.2 Effect of re-exposure to set-shifting on performance.
A) Number of trials to criterion by normal untreated naïve rats during first and the
second exposure to set-shifting were comparable (P>0.05). Student’s t-test; n=6
per group. B) Number of errors committed by rats performing set-shifting for
second time were comparable to the number of errors committed during their
performance on the first time (P>0.05). Student’s t-test; n=6 per group.
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4.4.1.2 Type of errors
During re-exposure to set-shifting, number of perseverative, regressive and neverreinforced errors were comparable between two runs of set-shifting
[F(1,5) = 0.1018, P=0.7626] (Figure 4.3; two-way ANOVA).

Figure 4.3 Effect of re-exposure to set-shifting on type of errors.
Number of perseverative, regressive and never-reinforced errors committed during both set-shifting
sessions were comparable (P=0.7626) two-way ANOVA; n=6 per group.
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Reduced Fyn kinase activity in the mPFC does not affect setshifting
4.4.2.1 Trials and errors to criterion
Intra-mPFC infusion of PP2 (3 ng/side) in naïve rats did not affect set-shifting.
Student’s t-test did not show any significant change in the number of trials to criterion
[t(12)=0.2269, P>0.05; n=7 each] (Figure 4.4 A) or the number of errors to criterion
[t(12)=0.1572, P>0.05; n=7 each] in rats infused with PP2 in comparison to vehicleinfused animals (Figure 4.4 B).

Figure 4.4 Effect of intra-mPFC infusion of PP2 on number of trials and errors to
criterion during set-shifting.
A) As compared to vehicle group, intra-mPFC infusion of Fyn kinase inhibitor PP2 (3 ng/side)
did not affect trials to criterion during set-shifting (P>0.05). Student’s t-test; n=7 per group. B)
Intra-mPFC PP2 treatment did not affect errors to criterion as compared to vehicle group
(P>0.05). Student’s t-test; n=7 per group.
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4.4.2.2 Type of errors
A two-way, mixed ANOVA with “treatment” as the between-subject factor and
“error type” as the within-subject factor, was used in the analysis of error profile as
described in the literature (Darrah et al., 2008; Floresco et al., 2008; Jones et al., 2014;
Snyder et al., 2015; Desai et al., 2017). Results showed that in naïve rats PP2 (3 ng/side)
treatment did not show any significant difference compared to control group in
committing perseverative errors while performing set-shifting task
[F(1,6) = 0.017, P=0.9003]. Furthermore, regressive and never-reinforced errors were
comparable between PP2 and vehicle groups (P>0.05) (Figure 4.5).

Figure 4.5 Effect of intra-mPFC infusion of PP2 on type of errors during set-shifting.
Number of perseverative, regressive as well as never-reinforced errors was comparable
between PP2 and vehicle groups (P>0.05). Two-way ANOVA; n=7 per group.
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Increasing PKA activity in the mPFC rescues co-infusion of D1
and NMDA blockers-induced impairment in set-shifting
4.4.3.1 Trials and errors to criterion
From our previous study, (see results 3.4.2), co-infusion of behaviourally subeffective doses of D1 receptor and NMDA receptor blockers (0.025 μg/side SCH 23390 +
0.125 μg/side MK-801; referred to as dual combination treatment) bilaterally into the
mPFC caused impairment in set-shifting in rats by increasing trials to criterion
[F(3,24) = 13.75, P<0.0001] as well as errors to criterion [F(3,24) = 10.7, P<0.0001]
(one-way ANOVA followed by Tukey’s post hoc test; n=7), whereas separate infusion of
the same low doses of SCH 23390 or MK-801 into the mPFC bilaterally did not affect
set-shifting (P>0.05).
In order to identify the potential signaling cascade downstream to D1 receptors in
mediating set-shifting, we augmented the activity of the most prominent D1 receptor
signaling pathway, the PKA signaling by co-infusing animals with dual combination
treatment and rolipram (2.5 μg/side). The number of trials required to achieve the
criterion [F(3, 24) = 13.75, P<0.0001] and the number of errors committed before
reaching the criterion [F(3, 24) = 10.7, P<0.0001] were significantly decreased compared
to those following the dual combination treatment (Figure 4.6 A,B; one-way ANOVA
followed by Tukey’s post hoc test). As hypothesized, co-infusion of rolipram with the
dual combination treatment significantly ameliorated the deficits. The group that received
co-infusion of rolipram and the dual combination treatment showed comparable number
of trials as well as number of errors to criterion with vehicle- or rolipram alone-treated
groups (P>0.05). Infusion of rolipram alone, however, did not affect set-shifting and the
observed trials and errors to criterion were similar to that of vehicle treatment (P>0.05),
indicating a lack of pro-cognitive effect of rolipram per se in naïve rats at this dose when
infused into the mPFC.
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Figure 4.6 Effect of rolipram on dual combination-induced set-shifting impairments.
A) Intra-mPFC infusion of dual combination (0.025 μg/side SCH 23390 + 0.125 μg/side MK-801)
significantly increased trials to criterion during set-shifting as compared to vehicle (***P=0.0002)
and rolipram alone groups (####P<0.0001). This effect was attenuated significantly by co-infusion of
rolipram (2.5 μg/side) ($$P<0.01). Number of trials taken by co-infused group and vehicle group
were comparable (P>0.05). One-way ANOVA followed by Tukey’s post hoc test; n=7 per group,
for rolipram alone group. B) Dual combination treatment (0.025 μg/side SCH 23390 + 0.125
μg/side MK-801) significantly increased number of errors committed during set-shifting as
compared to vehicle (**P<0.01) and rolipram per se (###P<0.001) groups. Combining rolipram
with dual combination significantly ameliorated this effect ($P<0.05). Further, co-infused group and
vehicle group committed comparable number of errors during set-shifting (P>0.05). One-way
ANOVA followed by Tukey’s post hoc test; n=7 per group.
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4.4.3.2 Type of errors
A significant main effects of treatment [F(3,18) = 7.862, P<0.001] as well as
error type [F(2,12) = 1376, P<0.0001], and a significant interaction between the factors
[F(6,36) = 10.42, P<0.0001] were seen. Post hoc testing revealed a significant increase in
perseverative errors committed following the dual combination group as compared to the
vehicle and rolipram alone (P<0.00001) (Figure 4.7). Co-infusion of rolipram (2.5
μg/side) with the dual combination treatment significantly decreased perseverative errors
compared to dual combination group (P<0.00001). The number of regressive and neverreinforced errors did not change across all groups tested (P>0.05).

Figure 4.7 Effect of rolipram on dual combination-induced increased perseverance.
Intra-mPFC treatment of dual combination (0.025 μg/side SCH 23390 + 0.125 μg/side MK-801)
significantly increased number of perseverative errors committed during set-shifting as compared
to vehicle and rolipram alone groups (****P<0.0001). This effect was ameliorated by rolipram coinfusion with dual combination ($$$$P<0.0001). Perseverative errors committed by co-infusion

group and the vehicle group were comparable (P>0.05). Further, regressive and never-reinforced
errors committed by all the groups were comparable (P>0.05). Two-way ANOVA followed by
Tukey’s post hoc test; n=7 per group.
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ERK phosphorylation in mPFC neurons is essential for setshifting
In order to identify the potential signaling cascade downstream of NMDA
receptors in mediating set-shifting, we attempted to inhibit phosphorylation of ERKs, a
common downstream signaling event of NMDA-mediated Ca++ influx, and an important
intermediary transducing NMDA signaling to the nucleus. To this end, groups of naïve
animals received intra-mPFC infusion of a MEK inhibitor PD98059 prior to testing.

4.4.4.1 Visual-cue learning and visual-cue retrieval before set-shifting
In different group of naïve animals, intra-mPFC infusion of MEK inhibitor;
PD98059 (2.5 g/side) did not affect visual-cue learning on visual-cue day (initial set
formation) as compared to vehicle group [t(12)=0.3234, P>0.05] (n=7; Figure 4.8 A;
student’s t-test). Further, visual-cue retrieval on set-shift day was not affected by
PD98059 treatment [t(6)=0.6882, P>0.05] (n=7; Figure 4.8 B; student’s t-test).
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Figure 4.8 Effect of PD98059 treatment on visual-cue learning and visual-cue retrieval
before set-shifting.
A) On the visual-cue discrimination day, prior intra-mPFC infusion of PD98059 (2.5 g/side)
did not affect learning of visual-cue discrimination strategy. The number of errors committed
during the visual-cue learning was comparable between PD98059 and vehicle groups
(P>0.05). Student’s t-test; n=7 per group. B) On the set-shift day (during the 20 trials prior to
the response discrimination task), intra-mPFC infusion of PD98059 (2.5 g/side) did not affect
retrieval of the memory from the previous day (visual-cue discrimination task), as the number
of errors committed during the 20 visual-cue trials was comparable between the groups

(P>0.05). Student’s t-test; n=7 per group.
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4.4.4.2 Trials and errors to criterion during set-shifting
Results indicate that bilateral infusion of PD98059 into the mPFC impair setshifting in naïve rats. PD98059 at dose 2.5 μg per side, significantly impaired animal’s
ability to shift from one strategy to the other. The number of trials to criterion
[t(12)=6.963, P<0.0001] as well as number of errors to criterion [t(12)=8.169, P<0.0001]
were significantly increased following PD98059 infusion compared or vehicle group
(n=7, each; student’s t-test; figure 4.9 A,B).

Figure 4.9 Effect of intra-mPFC infusion of PD98059 on trials and errors to criterion
during set-shifting.
A) Intra-mPFC infusion of the PD98059 (2.5 g/side) significantly increased number of
trials to criterion (****P<0.0001) as compared to vehicle group. Student’s t-test; n=7 per
group. B) Following infusion of PD98059 (2.5 g/side), rats committed significantly more
number of errors as compared to the vehicle group (****P<0.0001). Student’s t-test; n=7
per group.
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4.4.4.3 Type of errors
Two-way ANOVA revealed a significant main effect of treatment
[F(1,6) = 64.95, P=0.0002] as well as type of errors [F(2,12) = 58.57, P<0.0001]
following 2.5 μg per side of PD98059. Bonferroni’s multiple comparisons test showed
significant increase in perseverative errors following PD98059 infusion as compared to
vehicle-treated group (P<0.05) (Figure 4.10). PD98059 treatment did not affect
regressive or never-reinforced errors compared to vehicle group (P>0.05).

Figure 4.10 Effect of PD98059 treatment on type of errors during set-shifting.
Intra-mPFC infusion of PD98059 (2.5 g/side) prior to set-shifting increased number of
perseverative errors committed significantly as compared to vehicle group (*P<0.05).
Regressive and never-reinforced errors were remained unaffected by PD98059 (P>0.05).
Two-way ANOVA followed by Bonferroni’s multiple comparison test; n=7 per group.
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4.4.4.4 Omissions and latency to response
Number of omissions committed by PD98059 treated group was comparable to
vehicle group [t(12)=0.9487, P>0.05] (n=7; Figure 4.11 A; student’s t-test). Latency to
response for different type of trials was comparable between PD98059 and vehicle
groups [F(1,6) = 0.000244, P=0.9881] (n=7 Figure 4.11 B; two-way ANOVA).

Figure 4.11 Effect of PD98059 treatment on number of omissions and latency to response
during set-shifting.

A) Number of omissions committed by PD98059 treated group were comparable to vehicle
group (P>0.05). Student’s t-test; n=7 per group. B) Latency to response on extended levers
during different type of trials was not altered in both PD98059 and vehicle groups (P>0.05).
Two-way ANOVA; n=7 per group.
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Augmenting PKA activity does not affect the set-shifting deficits
caused by the inhibition of ERK phosphorylation
Our results so far showed that augmenting PKA activity ameliorates set-shifting
deficits caused by simultaneous inhibition of D1 and NMDA receptors (i.e., dual
combination treatment) and inhibiting ERK phosphorylation impairs set-shifting. PKA
activity may affect NMDA receptor-mediated ERK phosphorylation by targeting multiple
members along the pathway. The main proposed effect of phosphorylated ERK is on
transcriptional regulation. Interestingly, PKA translocate to the nucleus and capable of
affecting transcription including phosphorylating nuclear (cAMP response elementbinding protein) CREB independent of ERK phosphorylation. To verify whether
augmented PKA activity facilitates set-shifting via ERK phosphorylation or by other
cascades, we sought to augment PKA activity while inhibiting ERK phosphorylation in
animals performing set-shifting task. Rats were infused into the mPFC bilaterally with a
combination of rolipram and PD98059.

4.4.5.1 Trials and errors to criterion
Co-infusion of rolipram (2.5 μg/side) and PD98059 (2.5 g/side) did not cause
any improvement in PD98059-induced set-shifting deficit. Rolipram did not attenuate
PD98059-induced increased number of trials to criterion [F(2,18) = 24.08, P<0.0001]
and number of errors to criterion [F(2,18) = 22.38, P<0.0001] (one-way ANOVA
followed by Bonferroni’s test). Post hoc analysis showed that compared to the vehicle
group, co-infusion of rolipram and PD98059 resulted in significant increase in number of
trials to criterion (P<0.001) and number of errors to criterion (P<0.001). Importantly,
group that received co-infusion did not show any difference in number of trials or errors
to criterion as compared to the group infused with PD98059 alone (P>0.05) (Figure 4.12
A, B; one-way ANOVA).
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Figure 4.12 Effect of rolipram on PD98059-induced set-shifting impairments.
A) Intra-mPFC infusion of PD98059 (2.5 g/side) significantly increased number of
trials to criterion during set-shifting as compared to vehicle group (****P<0.0001). Coinfusing PD98059 with rolipram did not alter number of trials to criterion as compared
to PD98059 per se group (P>0.05). Further, co-infusion group showed significant
increase in trials to criterion as compared to vehicle group (***P<0.001). One-way
ANOVA followed by Bonferroni’s test; n=7 per group. B) Prior treatment with
PD98059, animals showed a significant increase in number of errors committed during
set-shifting as compared to vehicle group (****P<0.0001). Combined treatment of
rolipram with PD98059 did not decrease number of errors to criterion as compared to
PD98059 alone group (P>0.05). As compared to vehicle, combined infusion group
showed a significant increase in errors to criterion (***P<0.001). One-way ANOVA
followed by Bonferroni’s test; n=7 per group.
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4.4.5.2 Type of errors
Co-infusion of rolipram (2.5 μg/side) and PD98059 (2.5 g/side) did not attenuate
PD98059-induced increased perseverative errors. Combined treatment with rolipram and
PD98059 showed increased number of perseverative errors [F(1,6) = 21.89, P=0.0034]
(two-way ANOVA; Figure 4.13). Bonferroni’s post hoc analysis showed significant
increased perseverative errors following the combined treatment as compared to vehicle
group (P<0.01). Further, the number of perseverative errors seen following co-infusion
of rolipram and PD98059 did not differ from PD98059 alone treatment group (P>0.05).
There was no change in regressive and never-reinforced errors across groups (P>0.05).

Figure 4.13 Effect of rolipram on PD98059-induced increased perseverance.
PD98059 infusion in mPFC significantly increased number of perseverative errors as compared to
vehicle group (***P<0.001). Co-infusion of rolipram with PD98059 did not decrease number of
perseverative errors committed during set-shifting as compared to PD98059 group (P>0.05). In
comparison with vehicle group, animals receiving combined infusion showed a significant increase
in number of perseverative errors committed during set-shifting (**P<0.01). Two-way ANOVA
followed by Bonferroni’s test; n=7 per group.
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Figure 4.14 Representative histology and reconstruction of infusion cannulae tracks
in mPFC.
A) Photomicrographs showing that the bilateral infusion cannulae targeted the prelimbic
(PL) region of the mPFC in a representative animal. B) Schematic images of successive
coronal sections (adapted from Paxinos and Watson, 2007) showing the location of the
ends of the infusion cannulae in all animals used in the present study (n=48).
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4.5 Discussion
We found that, set-shifting impairments caused by intra-mPFC infusion of dual
combination were reversed co-infusion of PDE4 inhibitor- rolipram. Further, inhibiting
ERKs phosphorylation by MAPK inhibitor (PD98059) impaired set-shifting, while coinfusion of rolipram failed to ameliorate this impairment. Surprisingly, disrupting D1NMDA receptor cross-talk by inhibition of Fyn kinase in the mPFC did not affect setshifting performance.

Effect of PKA elevation on dual combination-induced set-shifting
deficits
We have shown that co-infusing D1 and NMDA receptor antagonists into the
mPFC impaired set-shifting at doses that when infused separately failed to affect setshifting performance (see 3.4.2). We found that increasing PKA levels in mPFC by intramPFC infusion of PDE4 inhibitor, rolipram, attenuated this dual combination treatmentinduced set-sifting impairments by decreasing the number of trials and errors to criterion
as well as the number of perseverative errors committed during set-shifting. Several
behavioural and electrophysiological studies have shown that PKA signaling cascade
may underlie the D1-NMDA receptor interaction in the PFC (Snyder et al., 1998; Aujla
and Beninger, 2001; Wang and O’Donnell, 2001; Baldwin et al., 2002a; FloresHernández et al., 2002; Tseng and O’Donnell, 2004; Kruse et al., 2009; Li et al., 2010;
Cahill et al., 2014). Increasing levels of PKA should, therefore, override the deleterious
effects of combined D1 and NMDA receptor antagonism, and our results support this
notion.
Rolipram was chosen based on its proven effectiveness for the PFC where the
most predominant PDE is of type 4 (Bolger et al., 1994; Suvarna and O’Donnell, 2002;
Richter et al., 2013). Our results are in accordance with Rodefer et al. (2012) who
showed that rolipram reversed set-shifting impairment caused by sub-chronic
phencyclidine (PCP, NMDA receptor antagonist) treatment in rats. In addition, number of
behavioural studies have reported effectiveness of rolipram in ameliorating cognitive
deficits due to NMDA antagonism (Zhang et al., 2000, 2004, 2005; Davis and Gould,
2005; Rodefer et al., 2005).
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We found that intra-mPFC infusion of rolipram alone in naïve rats did not
improve their set-shifting performance. In accordance with our results, Rodefer et al.
(2005) failed to see improvement in the performance in set-shifting using PDE10
inhibitors per se. However, Nikiforuk et al. (2016) reported improvement in set-shifting
performance in rats following infusion of a PDE10 inhibitor into the striatum. Our study
investigated the role of PFC and used an operant conditioning-based set-shifting task
where as Nikiforuk et al. (2016) studies striatal role and used a digging task-based setshifting, and strategies used by animals may differ between these different type of tasks.
From available preclinical data as well as our findings, it seems that PKA
activators (phosphodiesterase inhibitors) improve cognition in animals. Executive
functions including working memory, attention and set-shifting were found to be
improved (Nikiforuk et al. 2016; Zhang et al., 2000, 2004, 2005; Davis and Gould, 2005;
Rodefer et al., 2005). Potential use of rolipram like compounds as cognitive enhancers is
being tested in clinical trials by different pharmaceutical companies against cognitive
symptoms associated with CNS disorders including schizophrenia and Alzheimer’s
disease (Houslay et al., 2005; Kanes et al., 2007; García-Osta et al., 2012; Maurice et al.,
2014). Effect of inhibiting ERK cascade on set-shifting.
Our results for the first time indicate that inhibiting ERK phosphorylation in the
mPFC impaired set-shifting without affecting new learning or retrieval of memory. IntramPFC infusion of a MAPK inhibitor, (PD98059; 2.5 g/side), increased number of trials
and errors to criterion while performing set-shifting task and significantly increased
perseverative errors.
Stimulation of NMDA receptor induces activation of MAPK signaling cascade
leading to phosphorylation of ERKs and this plays an important role in learning
(Chandler et al., 2001; Krapivinsky et al., 2003; Shiflett et al., 2010; Shiflett and
Balleine, 2011). Although involvement of NMDA receptors in set-shifting is well
documented (Stefani et al., 2003; Stefani and Moghaddam, 2005), signaling mechanisms
downstream to receptors regulating set-shifting are not clear. Sarantis et al. (2009) has
reported that synergism between D1 and NMDA receptors in the PFC and hippocampus
is ERK-dependent. Recognizing a potential role of D1 and NMDA receptor synergism in
regulating set-shifting, we propose that the ERK signaling was disrupted following co-
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infusion of D1 and NMDA receptor antagonists in the mPFC causing set-shifting deficits
in rats (Figure 4.15). Effect of PKA activation on set-shifting deficit caused by inhibition
of ERK signaling
Our results showed that augmenting PKA levels in the mPFC ameliorates setshifting deficits caused by the combined blockade of D1 and NMDA receptors,
suggesting an important role for PKA in D1-NMDA receptor synergism in mediating setshifting. We also found that ERK phosphorylation, a downstream effect of NMDA
stimulation in the PFC, is critical for set-shifting. The most widely studied effect of ERK
phosphorylation is to affect transcriptional regulation. Interestingly, several transcription
factors, such as CREB, can be activated by phosphorylated ERKs as well as by activated
PKA trafficking into the nucleus. Consequently, we tested whether augmenting PKA
would compensate for impaired ERK phosphorylation in relevance to set-shifting. To this
end, we investigated effect of mPFC infusion of rolipram (2.5 g/side), the regimen
ameliorated the deficits following dual combination treatment, in presence of PD98059
(2.5 g/side) on set-shifting. Surprisingly, we did not see any effect of rolipram on
PD98059-induced set-shifting impairment. Therefore, it is likely that increased PKA
cannot compensate for the impaired ERK function, and ERK is acting downstream of
PKA.
Zhang et al. (2004) reported that PKA elevation mediated by PDE4 inhibitors
reverse the reference memory impairment caused by MAPK inhibitors in rats. In that
study, intra-hippocampus infusion of MAPK inhibitor U0126 impaired working and
reference memory in a radial arm maze task. Co-infusion of rolipram into the
hippocampus reversed the reference memory deficits with no effect on working memory.
Mechanism subserving reference memory might be different from that underlying setsifting. In fact, our results show that doses of blockers and receptor antagonists that
impair set-shifting do not affect memory formation or retrieval. Further, in the same
study, it was shown that, rolipram dose which reversed U0126-induced reference
memory deficit, did not ameliorate U0126-induced decreased ERK-phosphorylation. This
suggests that rolipram-mediated increased PKA activity might have reversed the
reference memory impairment via a different signaling cascade (Yan et al., 2016).
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Interestingly, activation of D1 receptor in mPFC, presumably activating PKA signaling,
also increased phosphorylation of NMDA receptor subunits, and this effect was blocked
by inhibitors of ERK phosphorylation (Nagai et al., 2007; Sarantis et al., 2009)
suggesting a cascade involving D1  PKA  ERK  NMDA, and our findings are in
support of this possibility (Figure 4.15). Thus, based on mentioned studies, we speculate
that phosphorylated ERKs may be regulating set-shifting behaviour by targeting
cytoplasmic substrates. It may be possible that phosphorylated ERKs are responsible to
phosphorylate NMDA receptors and increasing their functioning which ultimately
benefits set-shifting behaviour as proposed by Sarantis et al. (2009). Further, increased
activation of NMDA receptors found to increase activation of PKA (Roberson and Sweatt
1996; Jay et al. 1998; Nayak et al. 1998). As our results suggest that PKA restores
abnormal set-shifting behaviour, overall effect of increased ERKs phosphorylation should
promote set-shifting behaviour.
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Figure 4.15 Possible mechanisms underlying D1-NMDA receptor interaction
mediated set-shifting.
We observed that, co-infusing D1 and NMDA receptor antagonists in the mPFC at sub-

effective doses (dual combination) impaired set-shifting in rats. This impairment was
reversed by rolipram infusion in the mPFC. Further, inhibiting ERKs phosphorylation in
mPFC also caused set-shifting deficits and co-infusion of rolipram failed to reverse these
impairments. Based on available literature, it is possible that, D1 and NMDA receptor
antagonists at sub-effective doses act synergistically at the level of molecular signalling
affecting behaviour (Baldwin et al., 2002b). It is known that, D1 and NMDA receptors
stimulation triggers PKA and ERK pathways respectively (Chandler et al., 2001; Wang
et al., 2002). Further, PKA-ERK signalling cascades interact with each other where, D1
receptor stimulation or combining sub-effective doses of D1 and NMDA receptor
agonists resulted in increased phosphorylation of ERKs as well as NMDA and AMPA
receptor subunits; and this effect was blocked by MAPK inhibitor (Sarantis et al., 2012).
Based on our findings and the literature, we propose that, set-shifting is regulated by
PKA as well as ERK signalling and ERK is downstream to PKA as rolipram did not
reverse the set-shifting deficits caused by inhibition of ERK phosphorylation. Thus, it
seems that, set-shifting is regulated by D1  PKA  ERK  NMDA pathway.
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Effect of inhibiting Src kinase on set-shifting
Besides PKA and ERK signaling, evidence indicates that D1-NMDA receptor
interaction may involve direct physical coupling and functional cross-talk (Lee et al.,
2002; Fiorentini et al., 2003; Cepeda and Levine, 2006; Scott et al., 2006). This proteinprotein interaction is associated with phosphorylation and trafficking of NMDA receptor
subunits from cytoplasm to the cell membrane (Hallett et al., 2006; Gao and Wolf, 2008;
Hu et al., 2010). Fyn kinase (a member of Src family kinase) mediates D1-induced
increased surface expression of NMDA receptors in the PFC (Dunah et al., 2004; Hu et
al., 2010). Consequently, we predicted that Fyn kinase activity might mediate part of the
D1-NMDA interaction associated with set-shifting. Intra-mPFC infusion of PP2 (3
ng/side) did not affect set-shifting in rats. The dose of PP2 was chosen from previous
studies where PP2 impaired cognitive functions (Bevilaqua et al., 2003) and suppression
of NR2B phosphorylation (Grosshans and Browning, 2001; Lu et al., 2015). Unlike our
finding, Bevilaqua et al. (2003) reported that, infusing the same dose of PP2 into the
hippocampus impaired memory formation and retrieval. In addition, although mice with
Fyn mutation showed impaired LTP and spatial learning in water maze task (Grant et al.,
1992), they did not show spatial learning deficit in radial arm maze (Miyakawa et al.,
1996); neither they had deficits in conditioned taste aversion (Schafe et al., 1996). A
recent post-mortem study demonstrated evidence for reduced Src-family kinase activity
in the PFC of patients with schizophrenia (Hahn, 2011; Banerjee et al., 2015). Among
other cognitive symptoms, impaired behavioural flexibility and poor performance in
WCST are consistent findings in these patients (Rosse et al., 1991; Abbruzzese et al.,
1996; Haut et al., 1996; Waford and Lewine, 2010). Based on these evidence it was
proposed that impaired Src kinase function in the PFC might serve as a hub for the
cognitive dysfunction of schizophrenia (Banerjee et al., 2015). Although relatively less is
known of signaling mechanisms of Src kinase in the PFC, our results indicate that Src
kinase activity is unlikely playing a major role in set-shifting ability.

145

4.6 References
Abbruzzese M, Ferri S, Scarone S (1996) Performance on the Wisconsin Card Sorting
Test in schizophrenia: Perseveration in clinical subtypes. Psychiatry Res 64:27–33.
Agnoli L, Carli M (2011) Synergistic interaction of dopamine D1 and glutamate Nmethyl-d-aspartate receptors in the rat dorsal striatum controls attention.
Neuroscience 185:39–49.
Auger ML, Floresco SB (2017) Prefrontal cortical GABAergic and NMDA glutamatergic
regulation of delayed responding. Neuropharmacology 113:10–20.
Aujla H, Beninger RJ (2001) Hippocampal-prefrontocortical circuits: PKA inhibition in
the prefrontal cortex impairs delayed nonmatching in the radial maze in rats. Behav
Neurosci 115:1204–1211.
Baldwin AE, Sadeghian K, Holahan MR, Kelley AE (2002a) Appetitive instrumental
learning is impaired by inhibition of cAMP-dependent protein kinase within the
nucleus accumbens. Neurobiol Learn Mem 77:44–62.
Baldwin AE, Sadeghian K, Kelley AE (2002b) Appetitive instrumental learning requires
coincident activation of NMDA and dopamine D1 receptors within the medial
prefrontal cortex. J Neurosci 22:1063–1071.
Banerjee A, Wang HY, Borgmann-Winter KE, MacDonald ML, Kaprielian H, Stucky A,
Kvasic J, Egbujo C, Ray R, Talbot K, Hemby SE, Siegel SJ, Arnold SE, Sleiman P,
Chang X, Hakonarson H, Gur RE, Hahn CG (2015) Src kinase as a mediator of
convergent molecular abnormalities leading to NMDAR hypoactivity in
schizophrenia. Mol Psychiatry 20:1091–1100.
Bevilaqua LR, Rossato JI, Medina JH, Izquierdo I, Cammarota M (2003) Src kinase
activity is required for avoidance memory formation and recall. BehavPharmacol
14:649–652.
Bishop SF, Lauzon NM, Bechard M, Gholizadeh S, Laviolette SR (2011) NMDA

146

receptor hypofunction in the prelimbic cortex increases sensitivity to the rewarding
properties of opiates via dopaminergic and amygdalar substrates. Cereb Cortex
21:68–80.
Bolger GB, Rodgers L, Riggs M (1994) Differential CNS expression of alternative
mRNA isoforms of the mammalian genes encoding cAMP-specific
phosphodiesterases. Gene 149:237–244.
Bornstein RA, Nasrallah HA, Olson SC, Coffman JA, Torello M, Schwarzkopf SB
(1990) Neuropsychological deficit in schizophrenic subtypes: Paranoid,
nonparanoid, and schizoaffective subgroups. Psychiatry Res 31:15–24.
Braff DL, Heaton R, Kuck J, Cullum M, Moranville J, Grant I, Zisook S (1991) The
generalized pattern of neuropsychological deficits in outpatients with chronic
schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen
Psychiatry 48:891–898.
Cahill E, Salery M, Vanhoutte P, Caboche J (2014) Convergence of dopamine and
glutamate signaling onto striatal ERK activation in response to drugs of abuse. Front
Pharmacol 4:172.
Castner SA, Williams G V. (2007) Tuning the engine of cognition: A focus on
NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn 63:94–122.
Cepeda C, Levine MS (2006) Where do you think you are going? The NMDA-D1
receptor trap. Sci STKE 2006:pe20.
Chandler LJ, Sutton G, Dorairaj NR, Norwood D (2001) N-Methyl D-Aspartate
Receptor-mediated bidirectional control of extracellular signal-regulated kinase
activity in cortical neuronal cultures. J Biol Chem 276:2627–2636.
Collette F, Van der Linden M, Salmon E (1999) Executive dsfunction in Alzheimer’s
Disease. Cortex 35:57–72.
Dalton GL, Wang NY, Phillips AG, Floresco SB (2016) Multifaceted contributions by

147

different regions of the orbitofrontal and medial prefrontal cortex to probabilistic
reversal learning. J Neurosci 36:1996–2006.
Darrah JM, Stefani MR, Moghaddam B (2008) Interaction of N-methyl-D-aspartate and
group 5 metabotropic glutamate receptors on behavioral flexibility using a novel
operant set-shift paradigm. Behav Pharmacol 19:225–234.
Davis JA, Gould TJ (2005) Rolipram attenuates MK-801-induced deficits in latent
inhibition. Behav Neurosci 119:595–602.
Desai SJ, Allman BL, Rajakumar N (2017) Combination of behaviorally sub-effective
doses of glutamate NMDA and dopamine D1 receptor antagonists impairs executive
function. Behav Brain Res 323:24–31.
Déziel RA, Ryan CL, Tasker RA (2015) Ischemic lesions localized to the medial
prefrontal cortex produce selective deficits in measures of executive function in rats.
Behav Brain Res 293:54–61.
Duke LM, Kaszniak AW (2000) Executive control functions in degenerative dementias:
A comparative review. Neuropsychol Rev 10:75–99.
Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG
(2004) Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate
glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol
Pharmacol 65:121–129.
Elliott R (2003) Executive functions and their disorders: Imaging in clinical
neuroscience. Br Med Bull 65:49–59.
Enomoto T, Tse MT, Floresco SB (2011) Reducing prefrontal gamma-aminobutyric acid
activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble
schizophrenia. Biol Psychiatry 69:432–441.
Fiorentini C, Gardoni F, Spano P, Di Luca M, Missale C (2003) Regulation of dopamine
D1 receptor trafficking and desensitization by oligomerization with glutamate N-

148

methyl-D-aspartate receptors. J Biol Chem 278:20196–20202.
Flores-Hernández J, Cepeda C, Hernández-Echeagaray E, Calvert CR, Jokel ES,
Fienberg AA, Greengard P, Levine MS (2002) Dopamine enhancement of NMDA
currents in dissociated medium-sized striatal neurons: Role of D1 receptors and
DARPP-32. J Neurophysiol 88:3010–3020.
Floresco SB, Block AE, Tse MT (2008) Inactivation of the medial prefrontal cortex of
the rat impairs strategy set-shifting, but not reversal learning, using a novel,
automated procedure. Behav Brain Res 190:85–96.
Gao C, Wolf ME (2008) Dopamine receptors regulate NMDA receptor surface
expression in prefrontal cortex neurons. J Neurochem 106:2489–2501.
García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R (2012)
Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem
Neurosci 3:832-44.
Gauthier JM, Tassin DH, Dwoskin LP, Kantak KM (2014) Effects of dopamine D1
receptor blockade in the prelimbic prefrontal cortex or lateral dorsal striatum on
frontostriatal function in wistar and spontaneously hypertensive rats. Behav Brain
Res 268:229–238.
Gerdjikov TV, Ross GM, Beninger RJ (2004) Place preference induced by nucleus
accumbens amphetamine is impaired by antagonists of ERK or p38 MAP kinases in
rats. Behav Neurosci 118:740–750.
Gonzalez-Islas C, Hablitz JJ (2003) Dopamine enhances EPSCs in layer II-III pyramidal
neurons in rat prefrontal cortex. J Neurosci 23:867–875.
Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW (2000) Enhanced
and impaired attentional performance after infusion of D1 dopaminergic receptor
agents into rat prefrontal cortex. J Neurosci 20:1208–1215.
Grant SG, O’Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER (1992) Impaired long-

149

term potentiation, spatial learning, and hippocampal development in fyn mutant
mice. Science 258:1903–1910.
Grosshans DR, Browning MD (2001) Protein kinase C activation induces tyrosine
phosphorylation of the NR2A and NR2B subunits of the NMDA receptor. J
Neurochem 76:737–744.
Gurden H, Takita M, Jay TM (2000) Essential role of D1 but not D2 receptors in the
NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex
synapses in vivo. J Neurosci 20:RC106.
Hahn CG (2011) A Src link in schizophrenia. Nat Med 17:425–427.
Hallett PJ, Spoelgen R, Hyman B, Standaert D, Dunah A (2006) Dopamine D1 activation
potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit
trafficking. J Neurosci 26:4690–4700.
Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, Bloomfield SM (1996) On
the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry
Res 65:15–22.
Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a
therapeutic target. Drug Discov Today 10:1503-19.
Hill EL (2004) Evaluating the theory of executive dysfunction in autism. Dev Rev
24:189–233.
Hu JL, Liu G, Li YC, Gao WJ, Huang YQ (2010) Dopamine D1 receptor-mediated
NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal
cortical neurons. Mol Brain 3:20.
Hughes C, Graham A. (2002) Measuring executive functions in childhood: Problems and
solutions. Child Adolesc Ment Health 7:131–142.
Jay TM, Gurden H, Yamaguchi T (1998) Rapid increase in PKA activity during long-

150

term potentiation in the hippocampal afferent fibre system to the prefrontal cortex in
vivo. Eur J Neurosci 10:3302–3306.
Jones KM, McDonald IM, Bourin C, Olson RE, Bristow LJ, Easton A (2014) Effect of
alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting
impairment in rats. Psychopharmacology (Berl) 231:673–683.
Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP (2007) Rolipram: a
specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
Neuroscience 144:239-46.Krapivinsky G, Krapivinsky L, Manasian Y, Ivanov A,
Tyzio R, Pellegrino C, Ben-Ari Y, Clapham DE, Medina I (2003) The NMDA
receptor is coupled to the ERK pathway by a direct interaction between NR2B and
RasGRF1. Neuron 40:775–784.
Kreipike CW, Walker PD (2004) NMDA receptor blockade attenuates locomotion
elicited by intrastriatal dopamine D1-receptor stimulation. Synapse 53:28–35.
Kruse MS, Prémont J, Krebs MO, Jay TM (2009) Interaction of dopamine D1 with
NMDA NR1 receptors in rat prefrontal cortex. Eur Neuropsychopharmacol 19:296–
304.
Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, Wang YT, Niznik HB, Yu X min,
Liu F (2002) Dual regulation of NMDA receptor functions by direct protein-protein
interactions with the dopamine D1 receptor. Cell 111:219–230.
Li YC, Liu G, Hu JL, Gao WJ, Huang YQ (2010) Dopamine D1 receptor-mediated
enhancement of NMDA receptor trafficking requires rapid PKC-dependent synaptic
insertion in the prefrontal neurons. J Neurochem 114:62–73.
Liu DZ, Sharp FR, Van KC, Ander BP, Ghiasvand R, Zhan X, Stamova B, Jickling GC,
Lyeth BG (2014) Inhibition of SRC family kinases protects hippocampal neurons
and improves cognitive function after traumatic brain injury. J Neurotrauma
31:1268-76.
Lu W, Fang W, Li J, Zhang B, Yang Q, Yan X, Peng L, Ai H, Wang JJ, Liu X, Luo J,

151

Yang W (2015) Phosphorylation of tyrosine 1070 at the GluN2B subunit is
regulated by synaptic activity and critical for surface expression of N-methyl-Daspartate (NMDA) receptors. J Biol Chem 290:22945–22954.
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC (2014) Advances in
targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov13:290-314.
Missale C, Fiorentini C, Busi C, Collo G, Spano PF (2006) The NMDA/D1 receptor
complex as a new target in drug development. Curr Top Med Chem 6:801–808.
Miyakawa T, Yagi T, Kagiyama A, Niki H (1996) Radial maze performance, open-field
and elevated plus-maze behaviors in Fyn-kinase deficient mice: further evidence for
increased fearfulness. Brain Res Mol Brain Res 37:145–150.
Moghaddam B, Jackson ME (2003) Glutamatergic animal models of schizophrenia.
Annals of the New York Academy of Sciences, pp 131–137.
Monchi O, Petrides M, Petre V, Worsley K, Dagher A (2001) Wisconsin Card Sorting
revisited: distinct neural circuits participating in different stages of the task
identified by event-related functional magnetic resonance imaging. J Neurosci
21:7733–7741.
Moore TL, Schettler SP, Killiany RJ, Rosene DL, Moss MB (2009) Effects on executive
function following damage to the prefrontal cortex in the rhesus monkey (Macaca
mulatta). Behav Neurosci 123:231–241.
Mouri A, Noda Y, Noda A, Nakamura T, Tokura T, Yura Y, Nitta A, Furukawa H,
Nabeshima T (2007) Involvement of a dysfunctional dopamine-D1/N-methyl-daspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the
impairment of latent learning in a model of schizophrenia induced by phencyclidine.
Mol Pharmacol 71:1598–1609.
Nagai T, Takuma K, Kamei H, Ito Y, Nakamichi N, Ibi D, Nakanishi Y, Murai M,
Mizoguchi H, Nabeshima T, Yamada K (2007) Dopamine D1 receptors regulate
protein synthesis-dependent long-term recognition memory via extracellular signal-

152

regulated kinase 1/2 in the prefrontal cortex. Learn Mem 14:117–125.
Nai Q, Li S, Wang SH, Liu J, Lee FJ, Frankland PW, Liu F (2010) Uncoupling the D1-NMethyl-D-Aspartate (NMDA) receptor complex promotes NMDA-dependent longterm potentiation and working memory. Biol Psychiatry 67:246–254.
Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M,
Manabe T, Yamamoto T (2001) Characterization of Fyn-mediated Tyrosine
phosphorylation sites on glurepsilon 2 (NR2B) subunit of the N-Methyl-D-aspartate
receptor. J Biol Chem 276:693–699.
Nayak A, Zastrow DJ, Lickteig R, Zahniser NR, Browning MD (1998) Maintenance of
late-phase LTP is accompanied by PKA-dependent increase in AMPA receptor
synthesis. Nature 394:680–683.
Nikiforuk A, Potasiewicz A, Rafa D, Drescher K, Bespalov A, Popik P (2016) The
effects of PDE10 inhibition on attentional set-shifting do not depend on the
activation of dopamine D1 receptors. Behav Pharmacol 27:331–338.
Orellana G, Slachevsky A (2013) Executive functioning in schizophrenia. Front
Psychiatry 4:35.
Ozonoff S (1995) Executive functions in autism. Learning and Cognition in Autism, pp
199–219.
Paine TA, Cooke EK, Lowes DC (2015) Effects of chronic inhibition of GABA synthesis
on attention and impulse control. Pharmacol Biochem Behav 135:97–104.
Paine TA, Carlezon WA (2009) Effects of antipsychotic drugs on MK-801-induced
attentional and motivational deficits in rats. Neuropharmacology 56:788–797.
Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates sixth edition.
Elsevier Acad Press 170:547–612.
Perry RJ, Hodges JR (1999) Attention and executive deficits in Alzheimer’s disease. A

153

critical review. Brain 122:383–404.
Pulvirenti L, Swerdlow NR, Koob GF (1991) Nucleus accumbens NMDA antagonist
decreases locomotor activity produced by cocaine, heroin or accumbens dopamine,
but not caffeine. Pharmacol Biochem Behav 40:841–845.
Ragozzino ME (2002) The Effects of dopamine D1 receptor blockade in the prelimbic –
infralimbic areas on behavioral flexibility. Learn Mem 9:18–28.
Ragozzino ME, Wilcox C, Raso M, Kesner RP (1999) Involvement of rodent prefrontal
cortex subregions in strategy switching. Behav Neurosci 113:32–41.
Reddy LF, Waltz JA, Green MF, Wynn JK, Horan WP (2016) Probabilistic reversal
learning in schizophrenia: Stability of deficits and potential causal mechanisms.
Schizophr Bull 42:942–951.
Richter W, Menniti FS, Zhang HT, Conti M (2013) PDE4 as a target for cognition
enhancement. Expert Opin Ther Targets 17:1011–1027.
Rios Valentim SJ, Gontijo A, Peres MD, Rodrigues LC, Nakamura-Palacios EM (2009)
D1 dopamine and NMDA receptors interactions in the medial prefrontal cortex:
modulation of spatial working memory in rats. Behav Brain Res 204:124–128.
Roberson ED, Sweatt JD (1996) Transient activation of cyclic AMP-dependent protein
kinase during hippocampal long–term potentiation. J Biol Chem 271:30436–
30441.Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses
subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci
21:1070–1076.
Rodefer JS, Saland SK, Eckrich SJ (2012) Selective phosphodiesterase inhibitors
improve performance on the ED/ID cognitive task in rats. Neuropharmacology
62:1182–1190.
Rosse RB, Schwartz BL, Mastropaolo J, Goldberg RL, Deutsch SI (1991) Subtype
diagnosis in schizophrenia and its relation to neuropsychological and computerized

154

tomography measures. Biol Psychiatry 30:63–72.
Sarantis K, Antoniou K, Matsokis N, Angelatou F (2012) Exposure to novel environment
is characterized by an interaction of D1/NMDA receptors underlined by
phosphorylation of the NMDA and AMPA receptor subunits and activation of
ERK1/2 signaling, leading to epigenetic changes and gene expression in rat hippoca.
Neurochem Int 60:55–67.
Sarantis K, Matsokis N, Angelatou F (2009) Synergistic interactions of dopamine D1 and
glutamate NMDA receptors in rat hippocampus and prefrontal cortex: Involvement
of ERK1/2 signaling. Neuroscience 163:1135–1145.
Schafe GE, Stein PL, Park CR, Bernstein IL (1996) Taste aversion learning in Fyn
mutant mice. Behav Neurosci 110:845–848.
Scott L, Kruse MS, Forssberg H, Brismar H, Greengard P, Aperia A (2002) Selective upregulation of dopamine D1 receptors in dendritic spines by NMDA receptor
activation. Proc Natl Acad Sci U S A 99:1661–1664.
Scott L, Zelenin S, Malmersjö S, Kowalewski JM, Markus EZ, Nairn AC, Greengard P,
Brismar H, Aperia A (2006) Allosteric changes of the NMDA receptor trap
diffusible dopamine 1 receptors in spines. Proc Natl Acad Sci USA 103:762–767.
Seamans JK, Floresco SB, Phillips AG (1998) D1 receptor modulation of hippocampalprefrontal cortical circuits integrating spatial memory with executive functions in the
rat. J Neurosci 18:1613–1621.
Shiflett MW, Balleine BW (2011) Contributions of ERK signaling in the striatum to
instrumental learning and performance. Behav Brain Res 218:240–247.
Shiflett MW, Brown RA, Balleine BW (2010) Acquisition and performance of goaldirected instrumental actions depends on ERK signaling in distinct regions of dorsal
striatum in rats. J Neurosci 30:2951–2959.
Smith-Roe SL, Kelley AE (2000) Coincident activation of NMDA and dopamine D1

155

receptors within the nucleus accumbens core is required for appetitive instrumental
learning. J Neurosci 20:7737–7742.
Snyder GL, Fienberg AA, Huganir RL, Greengard P (1998) A dopamine/D1
receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32
kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA
receptor. J Neurosci 18:10297–10303.
Snyder KP, Hill-Smith TE, Lucki I, Valentino RJ (2015) Corticotropin-releasing factor in
the rat dorsal raphe nucleus promotes different forms of behavioral flexibility
depending on social stress history. Neuropsychopharmacology 40:1–33.
Stefani MR, Groth K, Moghaddam B (2003) Glutamate receptors in the rat medial
prefrontal cortex regulate set-shifting ability. Behav Neurosci 117:728–737.
Stefani MR, Moghaddam B (2005) Systemic and prefrontal cortical NMDA receptor
blockade differentially affect discrimination learning and set-shift ability in rats.
Behav Neurosci 119:420–428.
Su YA, Huang RH, Wang XD, Li JT, Si TM (2014) Impaired working memory by
repeated neonatal MK-801 treatment is ameliorated by galantamine in adult rats. Eur
J Pharmacol 725:32–39.
Suvarna NU, O’Donnell JM (2002) Hydrolysis of N-methyl-D-aspartate receptorstimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary
neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol Exp Ther
302:249–256.
Taylor JR, Birnbaum S, Ubriani R, Arnsten AF (1999) Activation of cAMP-dependent
protein kinase A in prefrontal cortex impairs working memory performance. J
Neurosci 19:1–5.
Tseng KY, O’Donnell P (2004) Dopamine-glutamate interactions controlling prefrontal
cortical pyramidal cell excitability involve multiple signaling mechanisms. J
Neurosci 24:5131–5139.

156

Tsuchida A, Fellows LK (2013) Are core component processes of executive function
dissociable within the frontal lobes? Evidence from humans with focal prefrontal
damage. Cortex 49:1790–1800.
Waford RN, Lewine R (2010) Is perseveration uniquely characteristic of schizophrenia?
Schizophr Res 118:128–133.
Wallace J, Marston HM, McQuade R, Gartside SE (2014) Evidence that the attentional
set shifting test in rats can be applied in repeated testing paradigms. J
Psychopharmacol 28:691–696.
Wang J, Chen Y, Carlson S, Li L, Hu X, Ma Y (2012a) Interactive effects of morphine
and scopolamine, MK-801, propanolol on spatial working memory in rhesus
monkeys. Neurosci Lett 523:119–124.
Wang J, O’Donnell P (2001) D(1) dopamine receptors potentiate nmda-mediated
excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex
11:452–462.
Wang M, Wong AH, Liu F (2012b) Interactions between NMDA and dopamine
receptors: A potential therapeutic target. Brain Res 1476:154–163.
Wang Z, Feng XQ, Zheng P (2002) Activation of presynaptic D1 dopamine receptors by
dopamine increases the frequency of spontaneous excitatory postsynaptic currents
through protein kinase A and protein kinase C in pyramidal cells of rat prelimbic
cortex. Neuroscience 112:499–508.
Yan K, Gao LN, Cui YL, Zhang Y, Zhou X (2016) The cyclic AMP signaling pathway:
Exploring targets for successful drug discovery (review). Mol Med Rep 13:3715–
3723.
Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M,
Rose GM, O’Donnell JM (2005) Effects of the novel PDE4 inhibitors MEM1018
and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in
rats. Psychopharmacology (Berl) 179:613–619.

157

Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O’Donnell JM (2004)
Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits
produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat
hippocampus. Neuropsychopharmacology 29:1432–1439.
Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O’Donnell JM (2000) Inhibition of
cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with
NMDA receptor antagonism. Neuropsychopharmacology 23:198–204.

158

Chapter 5

159

General discussion
Our studies investigated executive function (set-shifting), interaction between
dopamine and glutamate neurotransmitters regulating set-shifting and the signaling
mechanisms underlying the interaction. We found that, dopamine D1 and glutamate
NMDA receptors synergistically regulate set-shifting behaviour. We also found that D1NMDA interaction in the mPFC regulates set-shifting behaviour through PKA pathway.
Further, we found obligatory role of ERK signaling cascade in the mPFC mediating setshifting behaviour. For the first time, our studies explored role of molecular mechanisms
associated with set-shifting behaviour in rats. Our results propose possibility of targeting
molecular signaling pathways including PKA and ERKs for new drug discovery and
development.
In our first study, we examined the role dopamine and glutamate in regulating setshifting particularly when their activities are decreased only slightly. We hypothesized
that a minimal loss of glutamate and dopamine activity in certain brain areas as long as
they occur simultaneously would impair set-shifting and promote perseverative errors.
We employed an operant conditioning-based set-shifting task (Floresco et al., 2008) in
rats to determine behaviourally sub-effective doses of D1 or NMDA receptor antagonists
using dose-response studies. We then injected the behaviourally sub-effective doses of
D1 and NMDA antagonists together in naïve adult rats systemically to test the
hypothesis. Results showed that the combined systemic administration of behaviourally
sub-effective doses of NMDA and D1 receptor antagonists resulted in significant
impairment in set-shifting and increased perseverative errors. To our knowledge, this is
the first experimental evidence of an interaction between glutamate and dopamine
systems in regulating set-shifting behaviour in rats.
Based on post-mortem studies of schizophrenia brains consistently showing
evidence of considerable loss of GABA, dopamine or glutamate activity in the PFC, it
was widely believed that suppression of any one of these neurotransmitters may facilitate
impairment in executive function seen in schizophrenia (Okubo et al., 1997; Akil et al.,
1999; Goldman-Rakic et al., 2004; Gonzalez-Burgos et al., 2011; Hu et al., 2015).
However, recent studies using in vivo MRS and PET have identified that levels of
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glutamate, dopamine and GABA in the dlPFC and thalamus are normal or slightly altered
in schizophrenia patients in comparison to control groups (Théberge et al., 2007;
Ohrmann et al., 2007; Galińska et al., 2009; Rowland et al., 2009; Aoyama et al., 2011;
Seese et al., 2011; Szulc et al., 2011; Goto et al., 2012; Kegeles et al., 2012; Frankle et
al., 2015; Slifstein et al., 2015). Above MRS and PET findings suggest that the extent of
decrease of neurotransmitter function foreseen based on findings from post-mortem
studies, may not be applicable in living patients of schizophrenia, and if at all, the
differences may be subtle, perhaps due to compensatory mechanisms. Furthermore,
recent theories postulate that certain GABA abnormalities in schizophrenia might be
compensatory (Gonzalez-Burgos et al., 2011; Lewis, 2014). In addition D1 and NMDA
receptors are found to regulate cognitive functions in animal models (Baldwin et al.,
2002; Yang and Chen, 2005; Kruse et al., 2009; Wang et al., 2012a). Consequently, we
hypothesized that subtle abnormalities in the glutamate and dopamine neurotransmitter
systems in functionally-connected cortical and subcortical areas may cooperate
synergistically to impair executive function in schizophrenia, an experimental
consideration never addressed in previous preclinical rodent models as they only targeted
single neurotransmitter system at a time.
In our first study, we chose systemic route of drug administration to achieve
blockade of receptor function in multiple brain areas to be in agreement with the proposal
that executive function is regulated by neuronal circuits rather than single brain nucleus
(Floresco et al., 2009). As predicted results showed a significant increase in perseverative
errors following combined systemic administration of behaviourally sub-effective doses
of D1 and NMDA receptor antagonists. Interestingly, animal studies have shown that
inactivation of mPFC or MDT results in increased perseverative errors (Block et al.,
2007; Floresco et al., 2009). Our finding is also in line with the clinical literature where
schizophrenic patients performing WCST show increased perseverance (Crider, 1997;
Gooding et al., 1999; Prentice et al., 2008; Orellana and Slachevsky, 2013), points to
abnormal glutamate and dopamine function in multiple brain areas.
Based on preclinical studies Floresco (2013) proposed that inactivation of mPFC
or MDT or disconnecting these two nuclei results in increased perseverative errors while
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no change in regressive or never-reinforced errors. In our first study, systemic coadministration of NMDA and D1 antagonists produced a pattern of error profile with
increased perseverative errors that is similar to that proposed following damage to mPFC
and MDT or their connection (Block et al., 2007; Floresco et al., 2009). The results
pointed to mPFC and MDT as the most likely sites responsible for sub-effective doses of
D1 and NMDA receptor antagonists to act to produce deficits in set-shifting and
increased perseverative errors. Considering parallels with schizophrenia, we propose that
systemic administration of D1 and NMDA antagonists in naïve adult rats may model
certain aspects of cognitive deficits of schizophrenia and may form a potential high
throughput screening tool for testing drug candidates against cognitive symptoms of
schizophrenia.
As reasoned above, systemically-administered D1 and NMDA antagonist
combination has likely acted in the mPFC and MDT to impair set-shifting and to increase
perseverative errors. Since MDT receive very sparse dopamine innervation (Block et al.,
2007; Floresco et al., 2008, 2009) and dopamine abnormalities have never described in
the MDT of patients with schizophrenia, a disease characterized by executive functional
deficits and increased perseverative errors, we considered the mPFC as the most likely
candidate site. Consequently, in the second study, effects of combined blockade of D1
and NMDA receptors were investigated in the mPFC. However, it is still possible that D1
blockers might be acting in the PFC while NMDA blockers simultaneously acting in
MDT (or even the hippocampus) to cause their combined effects, as these are structurally
and functionally interconnected centers (Vertes, 2006; Floresco et al., 2009). In the
second study, following direct microinfusion of various doses of D1 and NMDA
antagonists separately into the mPFC bilaterally, we determined the behaviourally subeffective doses for each of these blockers. When these seemingly ineffective doses were
combined, increased number of trials and errors to criterion were evident while
performing set-shifting task, suggesting that the mPFC is one of the sites where
synergism between D1 and NMDA receptor antagonism might be occurring. The
impaired set-shifting was accompanied by significant increase in perseverative errors
following intra-mPFC co-infusions. This finding is in accordance with clinical studies in
schizophrenic patients performing WCST (Gooding et al., 1999; Prentice et al., 2008;
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Desai et al., 2017). It appears that PFC may play an important role in executive function
and its abnormality may manifest perseverative errors across species.
From our results, it seems that normal functioning of dopamine and glutamate
neurotransmitters is essential for executive functioning and abnormalities among them
lead to deficits. This notion opens doors for different strategies that could be used to
ameliorate executive dysfunction due to abnormal functioning of PFC. For example,
using drugs such as PDE4 inhibitors (rolipram) to increase the levels of cAMP, a
downstream effector of D1 stimulation, and obligatory activator of PKA cascade. Based
on our finding that co-infusion of D1 and NMDA blockade would cause impairment of
set-shifting while only one of these drugs at the same dose is unable cause this effect
suggesting that for normal set-shifting, co-incident activation of both D1-NMDA
receptors is necessary. Thus, we postulated use of multi-drug therapy strategy (i.e.,
combining antipsychotic drugs and cognitive enhancers) could be more beneficial rather
than conventional mono-therapy approach used so far in schizophrenia. Nevertheless,
more comprehensive understanding of the signaling cascade mediating set-shifting and
preventing perseverative errors is essential for future strategies to investigate potential
novel pharmacological targets. It is important to note that virtually nothing is known of
signaling beyond neurotransmitter receptors when it comes to set-shifting or
perseverance. Consequently, in the third study, we sought to investigate signaling
mechanisms underlying synergism between D1 and NMDA receptor antagonism in the
mPFC and those cascades important for set-shifting and preventing perseverative errors.
In the third study, we found that synergistic interaction between dopamine D1 and
glutamate NMDA receptor antagonists cause impairment of set-shifting and this effect
was reversed by intra-mPFC co-infusion of PDE4 inhibitor (rolipram). This is an
example of using adult naïve rats with combined infusion of D1 and NMDA antagonists
into the mPFC as a putative model of executive function deficits of schizophrenia to
investigate a potential effect of cognitive enhance, a proposal we made above. Findings
from this study suggested that D1-NMDA receptor interaction might use PKA signaling
pathway and elevating PKA levels using rolipram rescues set-shifting from effect of dual
combination of antagonists. Our findings are in accordance with previously published
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studies where PDE inhibitors successfully rescued animals from certain types of
cognitive deficits (Rodefer et al., 2005, 2012; Nikiforuk et al., 2016). In addition to this,
use of PDE inhibitors in number of CNS disorders has been initiated (Fore review,
Maurice et al., 2014). Post-mortem studies as well as imaging studies in schizophrenic
patients have showed abnormal dopamine neurotransmission in the PFC (Okubo et al.,
1997; Akil et al., 1999; Harrison, 2000; Abi-Dargham, 2003; Howes et al., 2015). This
lead to notion that, increasing D1 receptor activity in PFC would be beneficial for
cognition. In line with the hypothesis, Rosell et al. (2015) found that, D1 receptor agonist
treatment was helpful to improve cognition in patients with schizotypal personality
disorder (SPD). Although peripheral side-effects of the drugs tested prevented further
human studies (Salmi et al., 2004).
Another novel finding of our study is that, ERK signaling pathway is essential for
normal set-shifting and inhibition of ERK1/2 phosphorylation using a MAPK inhibitor
PD98059 resulted in increased perseverative errors. Interestingly, PD98059-induced setshifting impairments were not rescued by co-infusion of rolipram suggesting that ERK
pathway is downstream to PKA regulating set-shifting. Association of ERK signaling in
cognition has been studied extensively (Kelly et al., 2003; Duvarci et al., 2005;
Giovannini, 2006; Peng et al., 2010). In addition, evidence suggesting attenuated ERK
signaling in the PFC of schizophrenic patients has been reported in post-mortem studies
(Yuan et al., 2010; Hirayama-Kurogi et al., 2017). From our results and the literature
published on ERK signaling and its role in cognition, it seems that ERK could be a
potential target for development of drugs against cognitive deficits. In this regard, use of
ERK pathway modulators as therapeutic agents has been proposed in literature (Pearson
et al., 2001; Peng et al., 2010; Eishingdrelo, 2013). Researchers have investigated
possible use of modulators of ERK signaling in animal models of cognition, fragile X
syndrome, autism and reward (David Sweatt, 2001; Gerdjikov et al., 2004; Beninger and
Gerdjikov, 2005; Weng et al., 2008; Peng et al., 2010; Shiflett and Balleine, 2011; Wang
et al., 2012b, 2015; Papale et al., 2016; Sun et al., 2016). Further understanding of
signaling mechanisms is necessary for this line of effort to improve cognition.
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A Number of studies have explored ERK signaling and its association with
chronic or sub-chronic conditions including addiction, stress or memory consolidation. It
is generally considered that phosphorylated ERK1/2 would translocate to the nucleus and
interact with cAMP Response Element-Binding Protein (CREB) and other nuclear targets
(Roberson et al., 1999; Dudman et al., 2003; Waltereit and Weller, 2003). In our studies,
rats were subjected to set-shifting following acute intra-mPFC treatment with MAPK
inhibitor (PD98059). This suggests that, even acute blocking of ERK signaling impairs
set-shifting. Preliminary results from our laboratory suggest that in the context of setshifting, phosphorylated ERK1/2 might be acting mainly in the cytoplasm in mPFC
neurons, a proposal suggested previously by Sarantis et al. (2009). Although ERK
interactions with its nuclear targets like CREB cannot be ruled out.
In our study, inhibition of ERK phosphorylation with MAPK inhibitor (PD98059)
impaired set-shifting; and rolipram failed to attenuate this impairment. In addition to this,
disrupting cross-talk between D1 and NMDA receptors by inhibiting Fyn kinase did not
affect set-shifting. To our knowledge, this is the first study investigating signaling
mechanisms underpinning D1-NMDA receptor synergistic interaction regulating setshifting behaviour in rats.

5.1 Future directions
Taken together, present series of studies represent a big step forward towards
understanding executive function and underlying molecular mechanisms associated with
executive function deficits. We revealed molecular signaling pathways regulating setshifting behaviour and facilitating perseverative errors. This information will likely pave
future research endeavours in direction of developing potential drug candidates to
improve executive functions by targeting unconventional molecular pathways. With the
novel information, there are a number of new questions rise. From our studies, it seems
that multiple neurotransmitters act simultaneously to mediate successful executive
function. Future studies in animals as well as in human may use this approach to find out
potential therapeutic combinations of drugs to improve cognitive symptoms.
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In the final study, our results suggest critical and obligatory involvement of ERK
signaling mediating set-shifting. Further investigations are needed to find out what targets
in cytoplasm/nucleus ERK interact with to mediate set-shifting. Future research should
also address if NMDA/D1 independent activation of ERK pathway in mPFC would
ameliorate set-shifting deficits in putative models of schizophrenia.
Importance of dopamine-glutamate interactions in implications for development
of neuropsychiatric treatments has attracted researchers (Castner and Williams, 2007;
Wang et al., 2012a). For example, conventional medications used to suppress positive
symptoms of schizophrenia mainly act by blocking dopamine D2 receptors. On the other
hand, cognitive and negative symptoms are associated with D1 receptors in the PFC
(Seamans et al., 1998; Akil et al., 1999; Goldman-Rakic et al., 2004). Similarly,
glutamate NMDA receptors have become an important target as preclinical studies have
proven that, blocking NMDA receptor function induces positive, negative and cognitive
symptoms of schizophrenia whereas enhancing NMDA receptor functions potentially
reverse these impairments (Fletcher et al., 2005; Nabeshima et al., 2006; Mouri et al.,
2007; Hashimoto et al., 2008; Seillier and Giuffrida, 2009; Castañé et al., 2015).
Although the success of drug candidates modulating D1 or NMDA receptors seems very
promising in preclinical studies, recent clinical trials using these modulators have met
with limited success (Chaves et al., 2009; Tandon et al., 2010; Miyamoto et al., 2012;
Menniti et al., 2013; Dimitrelis and Shankar, 2016). The main reason behind failure of
compounds to pass clinical trials is that simply blocking or enhancing receptor functions
would result in unintended side-effects. Further, number of conventional preclinical
models cause impairments in animal behaviours following use of high dose of antagonists
which not the case in actual physiology. In this context, our results have indicated that
future studies should model cognitive deficits using minimal but combined suppression
of receptor/molecular function to mimic those changes might be happening in living
patients with tremendous compensatory mechanisms trying to normalize the defect.
Finally, targeting receptor interactions and molecular pathways might be a useful avenue
in correcting pathological imbalance in signaling mechanisms of neurotransmitters rather
than using molecules that bind to cell surface receptors.
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5.2 Limitations:
In pilot testing for our first study, we tested individual dose-dependent effects of
glutamate NMDA receptor antagonist (MK-801), dopamine D1 receptor antagonist SCH
23390 and GABA A receptor antagonist bicuculline on set-shifting behaviour following
subcutaneous injections. We obtained behaviourally sub-effective doses of each
antagonists. To study any interactions, we injected all three sub-effective doses of
antagonists simultaneously and rats were subjected to set-shifting task. Animals treated
with combined three antagonists showed noticeable abnormalities in behaviour including
reduced latency to response on the levers as well as they did not eat food pellets
following correct responses for 20-25 trials. On the other hand, rats treated with
combined behaviourally sub-effective doses of D1 and NMDA receptors showed only
behavioural flexibility deficits not affecting latency or omissions committed during setshifting. For the same reason, we used D1 and NMDA receptor antagonists in our first
study.
Further, in our first study, while testing dose-dependent effects of dopamine D1
receptor antagonist SCH 23390 on set-shifting behaviour, we observed that subcutaneous
injections of higher dose of SCH 23390 (0.01 or 0.02 mg/kg) caused noticeable motor
deficits and increased response latency, which resulted in a significant number of
omissions in both the visual-cue retrieval and set-shifting trials, and ultimately a failure to
complete the sessions (data not shown). For the same reason, we could not find effective
dose of SCH 23390 in our study and used lower dose of the antagonist which did not
affect locomotor activity and set-shifting in rats.In our last study (Chapter-IV), we
examined role of prefrontal cortical Fyn kinase in set-shifting behaviour in normal rats.
We found that used dose of Fyn kinase inhibitor-PP2 in the mPFC did not affect setshifting behaviour. Although, the dose of PP2 was chosen from previous studies where
PP2 impaired cognitive functions (Bevilaqua et al., 2003) and suppression of NR2B
phosphorylation (Grosshans and Browning, 2001; Lu et al., 2015), running western blot
studies to see if there is actual decreased NMDA receptor subunit phosphorylation would
confirm the previous findins.
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